Pharmaceutical Compositions Containing Adrenaline
A stable, amorphous epinephrine powder formulation with a maltodextrin carrier addresses the limitations of current auto-injectors, offering improved stability and bioavailability for transmucosal delivery, enhancing treatment efficacy and compliance.
Patent Information
- Application Number
- JP2024530530
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-25
- Filing Date
- 2022-11-25
- Publication Date
- 2024-11-08
Smart Images

Figure 2024541470000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to novel pharmaceutical compositions. The present invention also relates to methods for producing such compositions and formulating them into dosage forms. [Background technology]
[0002] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or common general knowledge.
[0003] In the treatment of acute disorders, a more rapid onset of pharmacological effect than can be achieved by oral drug delivery is often highly desirable. Administration principles that ensure that the drug is immediately available in the systemic circulation are more likely to result in a rapid onset of action.
[0004] Adrenaline, also known as epinephrine, is an endogenous hormone secreted primarily by the medulla of the adrenal gland, but also by a small number of neurons. Its main role in the body is as a stimulant of components of the sympathetic nervous system. Adrenaline is typically released during stressful situations and plays a key role in the fight-or-flight response by increasing blood flow to muscles, cardiac output, pupil dilation, and plasma glucose levels. It exerts this effect by binding to and stimulating alpha and beta adrenergic receptors.
[0005] Adrenaline was first isolated in the late 19th century and is now commonly used exogenously as a drug to treat, for example, allergic reactions (including anaphylaxis) and cardiac arrest, as well as croup and asthma.
[0006] For the treatment, particularly emergency treatment, of severe and / or acute conditions such as allergic reactions, including severe allergic reactions, anaphylaxis, and anaphylactic shock (which may be caused by insect venom from stings or bites, certain foods or drugs, and other chemicals such as latex), adrenaline is currently administered parenterally, for example by subcutaneous, intravenous, or intramuscular injection, along with other emergency medical interventions.
[0007] Individuals susceptible to such severe allergic reactions typically carry adrenaline auto-injectors to be self-administered in emergencies. Auto-injectors are typically single-use, disposable, spring-loaded syringes intended for self-administration by the patient or administration by untrained people or first responders.
[0008] The most common adrenaline auto-injector devices are sold under the brand names EpiPen® and EpiPen® Jr., but are also sold under other brand names such as Adrenaclick® and Auvi-Q®.
[0009] Injectable delivery means are often considered inconvenient: it is sometimes very difficult, if not impossible, for patients to self-administer drugs via a needle, sometimes requiring wasteful and time-consuming intervention by first responders and / or physicians to ensure compliance and avoid any unwanted or harmful effects.
[0010] Moreover, all of the above auto-injectors contain a solution of adrenaline, which is chemically very unstable. In fact, the EpiPen product label instructs that the product should be stored in its original packaging at room temperature (specifically 20°C to 25°C) and away from light and moisture. It cannot be refrigerated or frozen (e.g., to improve the stability of the product) as this would result in loss of performance of the device in an emergency (due to the need to inject a liquid solution through a thin needle).
[0011] Even under prescribed storage conditions, the shelf life of the EpiPen is only up to 24 months, and the shelf life of the EpiPen Jr is only up to 19 months. Furthermore, due to storage time during distribution, this shelf life is often reduced by as much as 12 months by the time end users are prescribed or obtain their devices. Users are instructed on the product label to replace the unit before its expiration date.
[0012] Due to the instability of epinephrine solutions, common to all auto-injectors, the EpiPen also contains an inspection window, through which the user is instructed to inspect the product on the product label, specifically to visually check for particulates (precipitate) or discoloration. If such particles and / or discoloration are present, the user is instructed to replace the unit, even if this occurs before the expiration date.
[0013] These factors combine to increase the number of unused and wastefully discarded adrenaline auto-injectors, but in addition, adrenaline solutions tend to contain stabilizers (antioxidants), more specifically sulfites, to which many patients are allergic, further limiting their use (see, e.g., Roth and Shields, Anesthesia & Analgesia, 98, 1499 (2004)).
[0014] Therefore, for the reasons stated above, there is a significant unmet clinical need for drug delivery compositions comprising adrenaline that have improved stability (physically and, more importantly, chemically).
[0015] Transmucosal administration of active ingredients is a viable alternative to parenteral administration, offering the possibility of delivering drug molecules directly into the systemic circulation via mucosal membranes (e.g., rectal, sublingual, buccal, pulmonary, and intranasal), potentially offering advantages such as increased patient compliance, improved drug bioavailability and therefore lower doses, more rapid onset of action, and reduced side effects.
[0016] However, transmucosal administration of drugs has its own very distinct problems. Unlike the gastrointestinal tract, which is a large organ containing a relatively large amount of fluid, spaces such as the oral and nasal cavities are relatively small and contain much less fluid, such as saliva and / or mucus. This necessarily results in a significant limitation on the amount of active ingredient that can be administered in a single dose.
[0017] Furthermore, although the gastrointestinal tract is a dynamic system, for the most part it is a somewhat "closed" system: Conversely, the rapid clearance mechanisms that occur in both the oral and nasal cavities often mean that there is also limited time available for absorption across mucosal surfaces for an already more limited amount of drug.
[0018] To address this issue, numerous formulation principles have been proposed, including bioadhesive formulation principles such as buccal patches for oral mucosal drug delivery (see, e.g., Shojaei, J. Pharm. Pharmaceutical Sci., 15, 19 (1998) and Gandhi, Advanced Drug Delivery Reviews, 43, 67 (1994)), and in situ gelling compositions for intranasal drug delivery (see, e.g., Bertan et al., Eur. J. Pharm. Sci., 27, 62 (2006)).
[0019] Solid transmucosal drug delivery systems may have considerable advantages in that they allow higher drug loading in the formulation.However, while solid drug delivery compositions are much more common when administered to the rectum, buccal, sublingual, and pulmonary mucosa, the majority of intranasal drug delivery systems remain in the form of liquid spray, typically aqueous solutions, and drug solubility is another factor that limits the amount of drug that can be absorbed.
[0020] The near ubiquity of liquid sprays for intranasal delivery is due to the lack of ease in formulating solid pharmaceutical formulations in the form of nasal powders: unlike the powders that are frequently used for inhalation of active ingredients into the lungs, there are very few intranasal powder formulations available on the market.
[0021] When formulated as dry powders, pulmonary drug delivery compositions typically take the form of "agglomerated" mixtures containing finely divided particles of the API on larger carrier particles. These agglomerates are intended to dissociate / break down upon inhalation or actuation of the device, leaving only fine particles of the active ingredient deposited in the lungs.
[0022] However, it is understood that such drug delivery systems do not work effectively in the case of intranasal drug delivery. This is because the presence of such fine particles poses a significant risk of exposure to the lung, which is not the intended site of administration. If the particle size of the drug is increased to avoid this problem, it is likely to be difficult to ensure proper interaction in the heterogeneous "interaction" mixture, which relies on substantial differences in the size of the two components to ensure interaction, which then leads to potential manufacturing problems such as separation during filling. Attempting to counter this by increasing the particle size of the corresponding carrier does not necessarily solve the problem, and may result in an inevitable increase in the mass of inactive excipients in the already finitely limited total mass of the dosage form, resulting in a reduced dose of active ingredient.
[0023] The difficulty of formulating dry powders for intranasal delivery is addressed in US Patent Application No. 2005 / 001411A1. In this document, it is stated that powders for nasal administration must be sufficiently fine to be efficiently carried by the gas stream and efficiently deposited in the nose, and also sufficiently coarse to facilitate the introduction of the powder into a suitable powder device, which is always necessary for intranasal administration. US2005 / 001411A1 apparently solves this problem by creating loosely formed secondary particles (agglomerates) of primary particles that contain the active ingredient. The agglomerates are said to have dimensions of several hundred microns, which allows for more efficient loading into a suitable intranasal administration (applicator, dispenser, or inhaler) device. Upon actuation of such a device and administration of the composition, the agglomerates apparently rapidly break down into primary particles of the active ingredient. These primary particles are said to be only a few microns in size, facilitating dissolution and subsequent intranasal absorption of the active ingredient.
[0024] As discussed above, transmucosal (e.g., intranasal) delivery of drugs intended for systemic absorption necessarily avoids first-pass metabolism, which is a component of oral administration. Drug metabolism occurs via chemical reactions with enzymes that can alter the chemical structure, physical structure, and / or biological activity of the active ingredient.
[0025] Most drugs are organic molecules that contain functional groups capable of undergoing such chemical reactions, and therefore are often susceptible to some form of chemical degradation when they come into contact with substances that can interact with those functional groups outside the body. As discussed above, the problem of chemical instability is particularly acute in the case of adrenaline.
[0026] As summarized by Kou and Zhou in Chapter 16 of the textbook Amorphous Solid Dispersions, Shah et al (Eds.), Springer (2014), when a drug is formulated in an amorphous, as opposed to crystalline, physical state, it is typically provided in a higher energy state and is therefore likely to be more chemically and physically unstable, presenting a challenge to the pharmaceutical manufacturer.
[0027] Therefore, chemical stability is often improved by providing drugs in a crystalline state through salt formation. The main purpose of salt formation is usually to increase the hydrophilicity of the active ingredient, addressing the problem of poor aqueous solubility and dissolution rate. However, in making salts, other physicochemical and biological concerns, such as chemical stability, can often be simultaneously addressed. For example, basic drugs (e.g., drugs that contain at least one amine group) are often provided in the form of acid addition salts, which are typically more chemically stable salts than the corresponding "free" amine bases.
[0028] However, while potentially providing the active ingredient in a form that can be more easily stored without chemical degradation and that is more efficient in terms of rate and / or extent of dissolution following administration, crystalline salts generally dissolve slower and are absorbed less efficiently across mucous membranes than when the corresponding active ingredient is provided in an amorphous and / or non-crystalline form, respectively.
[0029] Thus, active pharmaceutical ingredients formulated as amorphous solid dispersions generally offer the advantage of high bioavailability but typically present challenges in the form of reduced physical and chemical stability, whereas drugs formulated in crystalline and / or salt forms are generally more stable but tend to have lower bioavailability.
[0030] The latter problem can be particularly detrimental in the case of transmucosal drug delivery, such as intranasal or sublingual, which, as discussed above, limits the residence time of the drug in the relevant cavity necessary for absorption into the systemic circulation to occur. This, combined with poor permeability across mucosal membranes at physiological pH, can result in unacceptably low and / or slow transmucosal absorption to provide adequate therapeutic effect.
[0031] Many sophisticated formulation principles have been devised over the years to address the balancing act between solubility and permeability in transmucosal drug delivery systems, including the addition of pH modifiers that convert the ionized salt form of the active ingredient into a more permeable non-ionized state.
[0032] However, considering all of the aforementioned potential advantages it offers, there remains a need for improved solid (e.g., powder-based) transmucosal, and particularly intranasal, drug delivery systems.
[0033] In particular, in the field of transmucosal drug delivery, there remains a significant unmet clinical need for powdered drug delivery compositions that: (i) It is physically and chemically stable; (ii) in sufficient doses, and / or ● To provide the active ingredient in a form that is sufficiently penetrating to provide the required therapeutic effect (such as rate of onset and / or access to drug target) at the lowest possible dose (relatively speaking) and at the short residence time available in a transmucosal context, such as intranasally.
[0034] In the more specific area of intranasal drug delivery, there remains a significant unmet clinical need for such drug delivery compositions that include appropriately sized particles that enable both efficient: Filling of drug delivery devices, and • Deposition in associated (e.g. nasal) cavities.
[0035] Intranasal dry powder formulations are known, inter alia, from International Patent Applications Nos. 2010 / 142696 and 2019 / 038756, U.S. Patent Application No. 10,653,690 B2 and U.S. Patent Application No. 2018 / 0092839 A. See also U.S. Patent Nos. 7,947,742 (B2), 8,415,397 (B2) and 8,747,813 (B2).
[0036] Russo et al. (J. Pharm. Sci., 95, 2253 (2006)) disclose spray drying of an opioid analgesic compound, namely morphine, with a number of excipients. Spray-dried formulations are also disclosed by Vengerovich et al., Bulletin of Experimental Biology and Medicine, 163, 737 (2017), who attempted to microencapsulate the active ingredient in various materials, including 2-hydroxypropyl-β-cyclodextrin, with a view to developing sustained-release formulations based on polymeric carriers for acute care applications.
[0037] It has now been found that it is possible to formulate an adrenergic receptor modulator, such as adrenaline, in the form of an amorphous dry powder composition, for example by a process of spray drying the active ingredient together with a carrier material containing certain components, as disclosed below. Such compositions provide a surprising improvement in the stability of the active ingredient during storage and prior to administration, when compared with the formulations used in currently available devices, such as EpiPen. Such compositions may further provide improved bioavailability and / or absorption rate of the active ingredient after administration. Summary of the Invention
[0038] According to a first aspect of the present invention there is provided a pharma- ceutically acceptable composition in the form of a solid amorphous monoparticulate powder comprising: (a) a pharmacologically effective dosage of an adrenoceptor modulator or a pharma- ceutically acceptable salt thereof; (b) a pharma- ceutically acceptable carrier material, the carrier material comprising maltodextrin having a dextrose equivalent (DE) of greater than 15; and The pharma- ceutically acceptable compositions are hereinafter jointly referred to as "the compositions of the invention."
[0039] Adrenergic receptors (α 1A , α 1b , α 1c , α 1d , α 2a , α 2b , α 2c , α 2d Modulators (also known as "stimulants" or "agonists") of the stimulants (including β1, β2 and β3 subreceptors) include phenylephrine, oxymetazoline, methyldopa, clonidine, dexmedetomidine, lofexidine, dobutamine, mirabegron, dopamine, albuterol (salbutamol), formoterol, levalbuterol, olodaterol, salmeterol, pirbuterol, terbutaline, fenoterol, rimiterol, hexoprenaline, tretoquinol, carbuterol, tulobuterol, clenbuterol, procaterol, bitolterol, indacaterol, corterol, pseudoephedrine, ephedrine, more preferably norepinephrine, isoprenaline, and especially epinephrine (hereinafter referred to as "adrenaline" for consistency).
[0040] The composition of the present invention is in the form of an amorphous monoparticle powder. By "monoparticle" is meant that the particles forming the powder composition of the present invention comprise a homogeneous or heterogeneous mixture, in which the adrenergic receptor modulator or its salt is encapsulated in an amorphous state within the carrier material defined above, optionally in the presence of other ingredients. Thus, the particles of the powder composition of the present invention are provided as an amorphous composite of the adrenergic receptor modulator or its pharma- ceutically acceptable salt (hereinafter referred to as "active ingredient"), the carrier material described above, and optionally other ingredients.
[0041] Due to their amorphous nature, the compositions of the present invention may be completely amorphous and / or predominantly amorphous (e.g., more than about 50% amorphous, such as more than about 75% amorphous, including more than about 80% amorphous, such as more than about 90% amorphous or more than 95% amorphous, including more than about 99% amorphous). Alternatively, the compositions of the present invention may be less than about 50% amorphous, including less than about 25%, more preferably less than about 20%, such as less than about 10% amorphous, including less than about 5% amorphous or less than about 1% amorphous. The degree (%) of crystallinity may be determined by those skilled in the art using powder X-ray diffraction (PXRD). Other techniques such as solid-state NMR, FT-IR, Raman spectroscopy, differential scanning calorimetry (DSC) microcalorimetry, and calculation of true density may also be used.
[0042] As described below, despite being in an amorphous physical state, the compositions of the present invention exhibit surprising and unexpected physical and chemical stability and therefore may be provided in pharmaceutical forms that exhibit excellent shelf life when stored under normal storage conditions.
[0043] The composition of the present invention is produced by suitable techniques, at least initially in multiparticulate form (i.e. as powder).Generally, suitable techniques are classified into "solvent-based" methods, including spray drying, fluidized bed techniques, co-precipitation, supercritical fluid techniques, spray granulation, cryogenic techniques (including freeze drying), electrospinning and rotary jet techniques, or "fusion-based" methods, including melt granulation, melt extrusion, high shear mixing (e.g. KinetiSol®), milling and molten material on carrier techniques (e.g. Meltdose®).Preferred methods include freeze drying, and more preferably, the composition of the present invention is produced by spray drying process.
[0044] Such powders may be suitable for direct delivery to a patient via any pharma- ceutically acceptable route of administration, or may be provided as intermediate compositions that can be subsequently formulated into pharma- ceutically acceptable dosage forms for administration to one or more patients.
[0045] In this regard, pharmaceutical formulations and / or pharma- ceutically acceptable dosage forms are provided which are administered to a patient and include one or more compositions of the invention.
[0046] Thus, suitable pharmaceutical dosage forms may include liquid formulations, such as solutions, which may be prepared by dissolving (e.g., immediately prior to administration) a composition of the invention in a pharma- ceutically acceptable solvent (such as water), for delivery to such a patient, e.g., by injection or infusion.
[0047] Alternative pharmaceutical dosage forms may include liquid or semi-solid formulations such as liquid suspensions and / or gel compositions which may comprise a composition of the invention (e.g., particles thereof) suspended or dissolved in a suitable liquid or semi-solid carrier which may be loaded into a suitable dosage form or may be delivered, for example, by injection or infusion, or may be formed to form an implant or depot preparation after injection (e.g., subcutaneously or intramuscularly).
[0048] Alternatively, the composition of the present invention may be provided as part of an essentially solid pharmaceutical dosage form. The term "solid" will be well understood by those skilled in the art to include any form of matter that retains its shape and density when unconfined and / or in which the molecules are generally as tightly compressed as the repulsive forces between them permit. Thus, an essentially solid formulation is one in which at least about 80% is in such a form, such as at least about 90%, including at least about 95% (or at least about 99%).
[0049] In this regard, the compositions of the present invention may be provided in a multiparticulate form comprising a plurality of particles (e.g., simple powders, granules, pellets and / or beads) which may, individually and / or collectively, consist essentially of and / or comprise one or more such compositions.
[0050] Thus, the compositions of the present invention may be provided after preparation (e.g., by spray drying) in the form of a simple powder mixture, powdered microspheres, coated powdered microspheres, lyophilized liposomal dispersions, or combinations thereof.
[0051] When a pharma- ceutically acceptable dosage form of the invention "consists essentially of" particles of one or more compositions of the invention, this is understood to mean that the dosage form contains only one or more compositions of the invention, together with other features and / or components that do not substantially affect the basic and novel property(ies) of the dosage form. Alternatively, in situations where a dosage form of the invention "consists essentially of" one or more compositions of the invention, this may be understood to mean that the dosage form contains, in total, at least about 90%, such as at least about 95%, including at least about 97% by weight (e.g., about 99%) of one or more compositions of the invention.
[0052] Alternatively, the pharmaceutical dosage form may contain one or more compositions of the present invention in a single unit dosage form, such as a pessary, suppository or other form of insert, pill, capsule, cake, patch (e.g., buccal patch), film (e.g., buccal film), or tablet (e.g., sublingual tablet).
[0053] Capsules may be prepared by loading the compositions of the present invention as a spray-dried powder directly into pharma- ceutically acceptable capsules made from suitable materials designed for sublingual or, preferably, oral delivery, or by mixing the compositions with excipients prior to loading into such capsules for such delivery, which may include a granulation step as described below.
[0054] In this regard, the compositions of the present invention may be granulated into pellets or pills, but may also be formulated (ie, presented for administration) in the form of a dry, free-flowing powder.
[0055] "Dry" includes essentially free of water and other liquid solvents, including less than about 10%, such as less than about 6%, including less than about 5% or less than about 4%, more preferably less than about 3%, such as less than about 2%, e.g., less than about 1%, of the formulation is liquid such as water.
[0056] The flowability of the powder compositions of the present invention may be measured by standard techniques known to those skilled in the art, including bulk density measurements, or measurements made with a powder flow analyzer (e.g., those sold by Stable Micro Systems or Meritics, both in the UK), including powder flow rate dependency tests, caking tests, agglomeration tests, etc. A preferred measurement of flowability is the standard angle of repose, which may be performed using a rotating cylinder, a stationary funnel, or a tilting box.
[0057] In the context of the present invention, the term "free flowing" is intended to include powders that allow the compositions of the invention to be efficiently loaded into a drug delivery device during manufacture and / or that provide sufficient shot weight when expelled from the device (see below).
[0058] The term may also include that the powder exhibits an angle of repose of about 50° or less, such as about 45° or less, including about 40° or less, for example about 35° or less, more particularly about 30° or less, a bulk density of about 0.3 g / mL or more, for example about 0.4 g / mL or more, such as about 0.5 g / mL or more, more particularly about 0.6 g / mL or more, and / or a tap density of about 0.5 g / mL or more, such as about 0.6 g / mL or more, for example about 0.7 g / mL or more, particularly about 0.8 g / mL or more.
[0059] Suitable techniques for making dosage forms comprising dry powders or granules include simple dry blending, granulation (including dry granulation, wet granulation, melt granulation, thermoplastic pelletizing, spray granulation), extrusion / spheronization, or more preferably freeze-drying or spray drying (see below).
[0060] Dry granulation methods are also well known to those skilled in the art and include any technique in which primary powder particles are aggregated under high pressure, including, for example, slugging and roller compaction, as described below.
[0061] Wet granulation is well known to those skilled in the art and involves any technique involving agglomeration of a mixture of dry primary powder particles with a granulation fluid comprising a volatile inert solvent such as water, ethanol or isopropanol, alone or in combination, and optionally in the presence of a binder or binding agent. This technique may include passing the wet mass through a sieve to produce wet granules, which are then dried, preferably to a loss on drying of less than about 3% by weight.
[0062] Melt granulation is known to those skilled in the art to include any technique in which granules are obtained through the addition of a molten binder or a solid binder that melts during the process (these binder materials may include the pharma- ceutically acceptable carrier material of the composition of the present invention). After granulation, the binder is solidified at room temperature. Thermoplastic pelletization is known to be similar to melt granulation, but the plastic properties of the binder are used. In both processes, the resulting aggregates (granules) contain a matrix structure.
[0063] Extrusion / spheronization is well known to those skilled in the art to include any process involving dry mixing of the ingredients, wet massing with a binder, extrusion, spheronization of the extrudate into uniformly sized spheroids, and drying.
[0064] Spray granulation is known to those skilled in the art to include any technique that involves drying a liquid (solution, suspension, melt) and simultaneously accumulating granulation in a fluidized bed. Thus, in addition to generally including any spray coating granulation technique, this term includes the process in which foreign seeds (bacteria) are provided and granules are accumulated on them, as well as the process in which indigenous seeds (bacteria) are formed in the fluidized bed by abrasion and / or crushing. The sprayed liquid covers the bacteria and helps further agglomeration of the particles. It is then dried to form granules in the form of a matrix.
[0065] The term "lyophilization" includes lyophilization or cryodesication, and any low-temperature desolvation (e.g., dehydration) process in which the product is frozen, the pressure is reduced, and the frozen solvent (e.g., water) is removed by sublimation.
[0066] Alternatively, the compositions of the present invention may be provided in the form of tablets for oral, buccal and / or sublingual use. Such tablets may be formed, for example, by direct compression / compaction of the compositions of the present invention, optionally mixed with one or more suitable excipients, such as diluents, disintegrants, glidants and / or lubricants, as described, for example, in Pharmaceutical Dosage Forms: Tablets. Volume 1, 3 rd This can be achieved using techniques such as those described in "The Compression Press: A Novel Tablet Press," 1999 Edition, Augsburger et al. (eds.), CRC Press (2008) and documents cited therein. Suitable compression equipment includes standard tablet presses such as the Kilian SP300 or Korsch EKO, XP1, XL100, and XL200.
[0067] Suitable disintegrants that may be used for tablets (see, for example, Rowe et al, Handbook of Pharmaceutical Excipients, 6 th Disintegrants, as defined in ed. (2009), include cellulose derivatives such as hydroxypropylcellulose (HPC), low substituted HPC, methylcellulose, ethylhydroxyethylcellulose, calcium carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, modified cellulose gums; starch derivatives such as medium crosslinked starch, modified starch, hydroxypropyl starch, pregelatinized starch; and other disintegrants such as calcium alginate, sodium alginate, alginic acid, chitosan, colloidal silicon dioxide, docusate sodium, guar gum, magnesium aluminum silicate, polacrilin potassium, and polyvinylpyrrolidone. Combinations of two or more disintegrants may be used.
[0068] Preferred disintegrants include so-called "super disintegrants" (as defined, for example, in Mohanachandran et al, International Journal of Pharmaceutical Sciences Review and Research, 6, 105 (2011)), such as cross-linked polyvinylpyrrolidone, sodium starch glycolate, and sodium croscarmellose. Combinations of two or more super disintegrants can be used.
[0069] When disintegrants and / or superdisintegrants are used in tablets, they may be used in an amount (e.g., total) of 0.5 to 15% by weight based on the total weight of the composition, with a preferred range being 1 to 8% by weight, such as about 2 to about 7% by weight (e.g., about 5% by weight, such as about 4% by weight).
[0070] When present, binders are preferably used in an amount of 0.5 to 20% by weight based on the total weight of the tablet formulation. A preferred range is 1.0 to 15% by weight, such as about 2.0 to about 12% by weight (e.g., about 10% by weight). Suitable binding agents include cellulose gum and microcrystalline cellulose.
[0071] As described herein, the compositions of the present invention are preferably made by the process of spray drying.
[0072] Furthermore, whether in powder form or not, dosage forms containing the compositions of the present invention can be prepared using standard equipment by otherwise standard techniques known to those skilled in the art. In this regard, the compositions of the present invention can be combined with conventional pharmaceutical additives and / or excipients used in the art for the relevant preparations and incorporated into various types of pharmaceutical preparations using standard techniques to produce dosage forms containing the compositions of the present invention (see, for example, Lachman et al, 'The Theory and Practice of Industrial Pharmacy', CBS, 4 thedition (2015), 'Remington: The Science and Practice of Pharmacy', Troy (ed.), Elsevier, 23 rd edition(2020), and / or 'Aulton's Pharmaceutics: The Design and Manufacture of Medicines', Taylor and Aulton(eds.), Elsevier, 5 th (See the International Journal of Clinical Chemistry, 2017 edition).
[0073] Regardless of the method of manufacture, the compositions of the present invention are preferably suitable and / or formulated for transmucosal delivery of the active ingredient to the systemic circulation.
[0074] Those skilled in the art will appreciate that the term "transmucosal" means that, however administered to a patient, the composition is provided to the relevant mucosal surface in a form such that the active ingredient(s) can be absorbed across that mucosal surface after dissolution. Thus, relevant mucosal surfaces include the oral, nasal, ocular, vaginal, cervical, pulmonary and / or anorectal mucosa, more particularly the oral mucosa (including the buccal and sublingual mucosa) and nasal mucosa.
[0075] Thus, dosage forms containing the compositions of the present invention may be administered directly to a patient's mucosal surface (including pulmonary, rectal, vaginal, buccal, sublingual or intranasal) for transmucosal delivery of the active ingredient.
[0076] When administered to the sublingual mucosa, the compositions of the invention may, for example, be in the form of a sublingual tablet as described above, which may comprise disintegrants or disintegrating agents (which may be defined as any material capable of accelerating the disintegration / dispersion of such compositions of the invention to a measurable extent), which may be achieved, for example, by materials capable of swelling and / or expanding when contacted with an aqueous medium, as described below.
[0077] Alternatively, the compositions of the invention may be administered sublingually in the form of a powder, as described herein, which may be dispensed into the mouth and under the tongue from a suitable container, such as a capsule or sachet.
[0078] When the compositions of the invention are suitable and / or formulated for sublingual or, especially, intranasal administration, they are preferably administered in the form of a powder composition having a dosage of active ingredient of about 100 mg or less. Such sublingual and / or nasal powder compositions may comprise the composition of the invention mixed with other excipients, or may consist essentially of the composition of the invention as defined above.
[0079] The compositions of the invention suitable and / or formulated for intranasal administration are preferably provided by a dosage means suitable for nasal delivery. Such a dosage means may contain one, e.g., spray-dried powder composition of the invention, or may contain two or more such compositions in a reservoir of a suitable applicator. In the latter case, the dosage means contains two or more dosages of the composition of the invention, each of which contains a pharmacologically effective dose of the active ingredient(s).
[0080] Two or more compositions of the present invention can be administered intranasally either by repeated actuation of any device that contains or communicates with the administration means. Thus, the compositions of the present invention can be provided in a suitable device (e.g., a nasal applicator or dispenser (inhaler), such as those described below), and / or in a container or reservoir that is part of, is attached to, and / or is suitable for placement in association with such an applicator. Such a container or reservoir can contain one or more compositions of the present invention, each containing a pharmacologically effective dosage of the active ingredient.
[0081] In this manner, a suitable dosing means and / or nasal applicator may be actuated only once to deliver a single composition of the invention containing an appropriate dose of active ingredient following that actuation (i.e., a single-use dosage unit), may be actuated two or more times to deliver two or more compositions of the invention each containing an appropriate dose of active ingredient with each such actuation (i.e., a multi-use dosage unit), and / or may be refilled with a replacement source (e.g., a container or reservoir) of composition(s) of the invention containing one or more such compositions to provide single and / or multiple doses and / or dosing regimens.
[0082] Thus, the compositions of the present invention may be administered in the form of a plurality of particles, which particles may individually and / or collectively be composed of and / or comprise the compositions of the present invention.
[0083] Thus, the compositions of the present invention are prepared (initially) in the form of a solid, dry, free-flowing multiparticulate powder, as described above.
[0084] As mentioned above, the compositions of the present invention are provided in the form of amorphous monoparticle powders. They are not composed of a physical association of two or more separate, separate sets of particles of different components in the form of a mixture, such as an ordered or interactive mixture of smaller particles of active ingredient associated with larger, but separate, particles of chemically different carrier material. Nevertheless, the compositions of the present invention can be provided as small particles that can then be attached to separate larger carrier particles in the interactive mixture, such provision being useful in the case of dosage forms intended for inhalation, e.g., the lungs (see, for example, J.Drug Delivery,Art.ID 5635010,1-19(2018)).
[0085] As mentioned above, the process for making the compositions of the present invention allows for the formation of pharmaceutical products that exhibit excellent shelf life in terms of both physical and chemical stability when stored under normal storage conditions as defined herein.
[0086] The compositions of the present invention are preferably prepared by the process of spray drying, which will be understood by those skilled in the art to include any method of producing dry powders from liquids, including solutions or suspensions (including slurries), involving the use of hot gas to rapidly dry and convert a liquid stream into solid particles, including vaporized solvent, and solutes previously dissolved in solution, and / or particles previously suspended in the evaporated liquid.
[0087] Suitable spray drying equipment includes some form of atomization means, such as a spray nozzle, that disperses the liquid into a spray having a relatively uniform droplet size. Such means may include any means capable of producing a dry, free-flowing powder, and may include high pressure swirl nozzles, spinning disks and / or atomizer wheels, high pressure single-fluid nozzles, two-fluid nozzles and / or ultrasonic nozzles.
[0088] The spray dryer may be a single effect or a multiple effect spray dryer and may include an integrated and / or external vibrating fluidized bed, a particle separator, and / or a collection means which may be a drum or a cyclone.
[0089] According to a further aspect of the present invention there is provided a process for producing the composition of the present invention, the process comprising the steps of: i) mixing an adrenoceptor modulator or a pharma- ceutically acceptable salt thereof together with a pharma- ceutically acceptable carrier material in a suitable volatile solvent; ii) spray drying the mixture from step i).
[0090] Preferred volatile solvents include water, or lower alkyl alcohols (e.g., methanol, isopropanol, or, more particularly, ethanol), hydrocarbons (e.g., C 5-10 Examples of suitable solvents include organic solvents such as alkane, haloalkane (eg, dichloromethane), dimethylformamide, dimethylsulfoxide, ethyl acetate, acetone, and the like, or mixtures thereof.
[0091] Preferably, the active ingredient, the pharma- ceutically acceptable carrier material(s) as defined herein, and other optional ingredients as described herein (e.g., alkyl sugars as described below) are mixed together with a solvent to obtain a solution that can be spray dried.
[0092] Pharmaceutically acceptable carrier materials used in the compositions of the invention should be solid under normal storage conditions, suitable (and / or approved) for pharmaceutical use and / or transmucosal (e.g. sublingual or especially intranasal) delivery, be able to maintain their physical and / or chemical integrity and / or not affect the physical and / or chemical integrity of the active ingredient and / or any other ingredients (such as alkyl sugars) that are or may be present in the composition.
[0093] It is well known that obtaining a solid composition such as a powder that is both chemically and physically stable can present significant difficulties. If the physical form of the composition changes under normal storage conditions (e.g., from a free-flowing powder to agglomerates that are difficult to expel), the dose of the active ingredient can become unreproducible. This is particularly true when dispensing the composition from or through the nasal applicator described herein, where such agglomeration can result in a complete inability to dispense the active ingredient, which can be fatal in an emergency.
[0094] The compositions of the present invention may have a minimum shot weight as measured by an individual powder shot weight of about 80% of the target weight, such as about 85% (e.g., about 90%) up to about 120% (e.g., about 115%, such as about 110%), and / or an average powder shot weight of about 90% (e.g., about 95%) up to about 115% (e.g., about 110%, such as about 105%).
[0095] Similarly, in the case of multiple dose units containing two or more doses of the composition, such stability is important to ensure reproducibility of the dose of the active ingredient over time. Any of these issues may have adverse effects on the subject's health and / or may place the subject's well-being at serious risk.
[0096] For certain compositions of the present invention, exposure to atmospheric water may result in a powder composition with poor solid-state stability. For example, exposure to certain (e.g., relatively high) relative humidities may affect the physical form of the composition, for example, by deliquescence and / or by lowering the glass transition temperature of the composition and / or individual components of the composition, such as the carrier material, or in another way.
[0097] Thus, the compositions of the present invention, as well as pharmaceutical formulations and dispensing means (such as nasal applicators) containing them, are preferably packaged in containers that substantially prevent the ingress of atmospheric water under the storage conditions defined herein. Such containers may include packaging materials such as blister packs for tablets and capsules, as well as heat-sealed aluminum pouches and / or thermoformed plastics. Such containers may also include desiccants, such as silica gel and / or suitable molecular sieves, for example with a pore size of 3 Å or 4 Å.
[0098] The phrase "maintaining physical and chemical integrity" essentially means chemical stability and solid state stability.
[0099] "Chemical stability" includes that any composition of the present invention, when formulated into a pharmaceutical preparation or dosage form and / or loaded into a pharmaceutical dispensing device such as a nasal applicator or reservoir therefor (with or without appropriate pharmaceutical packaging), or otherwise capable of being stored in isolated solid form under normal storage conditions with only a minor degree of chemical degradation or decomposition of either the composition itself or any of the active ingredients contained therein.
[0100] The term "chemical stability" also includes "stereochemical" and / or "constitutional" stability, which refers to the resistance to stereochemical transformation, such as racemization, at one or more chiral centers within the molecule of an active ingredient. This is particularly important in the case of adrenaline, where the R enantiomer (i.e., L-(-)-epinephrine) is the active enantiomer and the S enantiomer (i.e., D-(+)-epinephrine) is less active and therefore may be considered an impurity.
[0101] "Physical stability" or "solid state stability" includes that any composition of the present invention, when formulated into a pharmaceutical formulation or dosage form and / or loaded into a pharmaceutical dispensing device such as a nasal applicator or reservoir therefor (with or without appropriate pharmaceutical packaging), or otherwise under normal storage conditions, may be stored in an isolated solid form with only minor degrees of solid state change (e.g., crystallization, recrystallization, loss of crystallinity, solid state phase transition (e.g., between a glassy or rubbery state, or to an aggregated form)), hydration, dehydration, solvation, or desolvation of either the composition itself or any of the active ingredients contained therein.
[0102] Examples of "normal storage conditions" for the compositions of the invention, whether in the form of a pharmaceutical formulation or dosage form and / or loaded into an applicator, device, drug reservoir (such as a canister or container) or otherwise, include extended periods of time (i.e., greater than about 12 months, such as about 6 months), at temperatures of about -50°C to about +80°C (preferably about -25°C to about +75°C, such as about 50°C), and / or at pressures of about 0.1 to about 2 bar (preferably atmospheric pressure), and / or exposure to at least about 460 lux of UV / visible light, and / or a relative humidity of about 5 to about 95% (preferably about 10 to about 40%).
[0103] Under such conditions, the compositions of the invention (and / or the active ingredients contained therein), whether contained in an applicator or its reservoir (with or without suitable pharmaceutical packaging) or otherwise, as appropriate, may be found to be chemically degraded / decomposed and / or solid state converted to less than about 15%, more preferably less than about 10%, especially less than about 5%.Those skilled in the art will appreciate that the above upper and lower limits of temperature and pressure represent the extremes of normal storage conditions, and that certain combinations of these extremes will not be experienced during normal storage (e.g., a temperature of 50°C and a pressure of 0.1 bar).
[0104] Such chemical stability, and especially physical stability, is important in solid compositions such as powders to ensure that an appropriate dose is delivered to the patient.
[0105] Notwithstanding the above definition of "normal storage conditions," the compositions of the present invention (and / or active ingredients contained therein), whether contained in an applicator or a reservoir therefor (with or without appropriate pharmaceutical packaging), may be chemically and / or sterically degraded by less than about 5%, including less than about 4% (less than about 3%, such as less than about 2.5% (e.g., less than about 2%), including less than about 1.5%, and / or even less than about 1%), after storage of: (a) at 40° C. and 75% relative humidity for at least about 3 months, including at least about 6 months or at least about 12 months; (b) at less than about 30° C., such as about 30° C. or about 25° C., and / or at a relative humidity of, for example, about 65%, such as about 60%, for at least about 18 months, such as at least about 24 months, including at least about 36 months; and / or (c) UV light of greater than approximately 1 million lux for at least approximately 18 hours.
[0106] Thus, the compositions of the present invention may be stored within a dosage form such as an applicator or its reservoir (with or without appropriate pharmaceutical packaging) or otherwise at any temperature (e.g., as low as about -20°C) up to about 25°C (e.g., up to about 30°C), preferably with fluctuations up to about 40°C or even up to about 50°C.
[0107] The compositions of the present invention comprise a carrier material composed at least in part of a maltodextrin having a DE of more than 15, for example up to 47, such as 38, 39, preferably 23, 24, 25 or 26, or more preferably 16, 17, 18, 20, 21 or 22, and especially 19. Those skilled in the art will understand that maltodextrins with a DE of more than 20 are referred to as "glucose syrups".
[0108] Maltodextrins are classified by DE; the higher the DE value, the shorter the average length of the glucose chains. Thus, maltodextrins with a DE above 15 have a lower average molecular weight than those with a DE below 15. All maltodextrins are mixtures of polysaccharides with different chain lengths, and maltodextrins with a DE above 15 have fewer sugar units of higher molecular weight.
[0109] Maltodextrins suitable for use in the compositions of the present invention must nevertheless have a sufficiently high molecular weight such that, when used in any given amount, they can form a suitable carrier material for the active ingredient, including providing an adequate degree of physical stability.
[0110] More preferred pharma- ceutically acceptable carrier materials that may be used in the compositions of the present invention include combinations of related maltodextrin and disaccharide components. Preferred disaccharides include maltitol, sucralose, sucrose, isomalt, maltose, preferably lactose (including β-D-lactose and α-D-lactose, especially α-D-lactose monohydrate), and especially trehalose.
[0111] It has been found that maltodextrins with lower DE, such as maltodextrins with a DE of 12 or less, contain longer polysaccharide chains (e.g., having about 24 glucose units or more) and can form aggregates when present in aqueous solution with other ingredients, such as active ingredients like sucrose esters and / or surfactants, and have a tendency to form helical structures that result in a cloudy solution prior to spray drying. This cloudiness can cause stability and / or processability problems during manufacturing, necessitating the use of an in-line filter.
[0112] It has been found that the aforementioned haze problem can be alleviated to some extent by reducing the relative amount of maltodextrin included in the compositions of the present invention, although this can be achieved by increasing the amount of other ingredients such as other carrier materials (e.g., disaccharides), active ingredients, or certain additives such as sucrose esters; the higher the molecular weight of the maltodextrin, the less needs to be included and the more, e.g., disaccharides or sucrose esters, needs to be added to alleviate the haze.
[0113] When adding more sucrose esters to reduce this haze, more may need to be added than is necessary to provide the appropriate (e.g., physical, chemical and / or biological) effect, including absorption-enhancing effects, as described herein. Conversely, increasing the amount of disaccharide relative to maltodextrin in the carrier material may have a negative impact on the Tg and therefore the solid state stability of the compositions described herein.
[0114] It has been found that such problems can be reduced, and perhaps avoided altogether, by using an entirely different maltodextrin, i.e., one having a higher DE, such as one having a DE greater than 15, e.g., a DE of 18, 20, or more preferably a DE of 19.
[0115] Mixtures from any of the foregoing lists of disaccharides and / or maltodextrins having a DE greater than 15 may be used.
[0116] The amount of carrier material that may be employed in the compositions of the present invention (whether a unit dose of the composition is included in a dosage form or otherwise) is typically in the range of about 5% to about 99.9% by weight, including about 50% to about 75% by weight (e.g., about 25% by weight, including about 35% by weight) to about 85% by weight, including up to about 99% by weight (e.g., up to about 95% by weight or about 90% by weight), based on the total weight of the composition.
[0117] Whether provided as a combination of materials or otherwise, the carrier material is preferably capable of resulting in the composition of the present invention having a glass transition temperature (Tg) of: (a) is capable of being readily formulated into a pharmaceutical formulation or dosage form and / or its production in a hard and / or brittle, "glassy," amorphous, powdered physical form that can be readily loaded into a suitable dispensing means, such as a nasal applicator as described herein, or a drug reservoir and / or container within or associated with such an applicator; and (b) sufficiently high that after such pharmaceutical formulation, dosage form, or dispensing means, such as such applicator or reservoir, is packaged as described herein and thereafter subjected to an elevated external temperature (e.g., up to about 50° C. to about 80° C.), the composition remains in its glassy state rather than converting to a more viscous or rubbery state, and / or a crystalline state.
[0118] Such extreme external temperatures are often experienced inside vehicles (e.g., first responders') in warm and / or sunny climates, where such vehicles are frequently parked under the hot sun for long periods of time, and the resulting heat can be enormous. If the Tg of the (e.g., powder) composition is low, the composition may transform into such a viscous / rubbery state after exposure to such high temperatures, which may result in inefficient dosing of the composition of the present invention, such as inefficient release of the composition (and also the dose(s) of active ingredient) from the dosing means, such as the applicator or a reservoir contained therein, when the dosing means or applicator is actuated. Furthermore, a Tg that is too low may affect the disintegration and / or dissolution of the composition of the present invention in the form of a tablet for sublingual or oral use.
[0119] In this regard, the lowest measurable Tg of the composition of the present invention is preferably at least about 35°C, including at least about 40°C, such as at least about 50°C, such as at least about 55°C, including at least about 60°C, when measured at a relative humidity of up to about 35%, such as up to about 30%, including up to about 25% (e.g., up to about 20%, such as less than about 15%, e.g., less than about 10%). The "lowest measurable Tg" includes that the composition of the present invention may include particles that are heterogeneous in nature. In particular, the particles may include distinct regions of carrier materials, or a composite mixture thereof, and thus may have individual and distinct Tg values. It will be apparent to those skilled in the art that the lowest measurable Tg value will have a strong impact on the physical stability of the composition.
[0120] It has been found that the compositions of the present invention can provide an adequate level of physical and chemical stability of the compositions and active ingredients, particularly adrenaline and its salts. Indeed, as described below, the degree of chemical stability in particular is notable in comparison to currently available products containing adrenaline for the treatment of allergic reactions, such as EpiPen.
[0121] Thus, a particularly preferred combination of carrier materials includes trehalose and a maltodextrin having a DE greater than 15, such as maltodextrin 19 DE. The inventors have found that such combinations of carrier materials can be spray dried in appropriate ratios together with the active ingredient and, if present, alkyl sugars to produce compositions of the invention that have both the desired physical and chemical stability under normal storage conditions as defined herein.
[0122] It has been found that when used as the primary component of the carrier material, the relative amounts of the disaccharide and maltodextrin components can be adjusted to ensure a desired level of physical and / or chemical stability of the active ingredient while at the same time not lowering the Tg of the composition of the present invention in a manner that affects its physical stability.
[0123] Depending on the active ingredient used, it has been found that ratios of disaccharide:maltodextrin of about 50:1 to about 1:50 by weight based on the total weight of the composition can work. Preferred ratios are in the range of about 10:1 to about 1:40 (including up to about 1:30 or up to about 1:20), for example about 7:1 to about 1:5, including about 5:1, such as about 4:1, about 3:1, or about 2:1, for example about 1:10, such as about 1:8, including 1:3 or 1:2, more preferably about 8:1 (e.g., about 7:1, about 3:1, about 2:1, or about 1:1) to about 1:8 (e.g., about 1:3 or about 1:2) disaccharide:maltodextrin based on the total weight of the composition.
[0124] Regardless of their proportions in the final mixture, the compositions of the present invention can be prepared by spray drying the relevant ingredients to form a composite carrier material either before spray drying that carrier material with other essential ingredients to form the powder composition of the present invention. More preferably, the compositions of the present invention can be made in situ by spray drying all of the essential components of the compositions of the present invention together.
[0125] Combinations of adrenoceptor modulators or salts thereof may be used in the compositions of the present invention.
[0126] Salts of adrenergic receptor modulators are known in the art and are described in Martindale-The Complete Drug Reference, 40 th Edition, Pharmaceutical Press, London (2020) and the documents cited therein, the relevant disclosures of all of which are incorporated herein by reference.
[0127] Otherwise, pharma- ceutically acceptable salts include acid addition salts and base addition salts, which may be formed by conventional means, for example, by reacting the relevant active ingredient in free acid or free base form with one or more equivalents of the appropriate acid or base, optionally in a solvent or in a medium in which the salt is insoluble, followed by removal of the solvent or medium using standard techniques (for example, by vacuum, lyophilization, or filtration).Salts may also be prepared using techniques known to those skilled in the art, such as, for example, by exchanging a counterion of a compound of the present invention in the form of a salt with another counterion using a suitable ion exchange resin.
[0128] Particular acid addition salts which may be mentioned include carboxylates, such as succinates, tartrates, formates, acetates, benzoates, oxalates, fumarates, maleates, xinafoate, etc.; sulfonates, such as methanesulfonates, ethanesulfonates, toluenesulfonates, etc.; halide salts, such as hydrochlorides, hydrobromides, etc.; sulfates and phosphates, such as sulfates or phosphates.
[0129] Particular salts of adrenaline that may be mentioned include the bitartrate salt.
[0130] When the composition of the present invention is made by the above-mentioned solvent-based process, including by the process of spray drying, this may result in the presence of the active ingredient in a form that is no longer in the form of a crystalline salt, since it is freely dispersed and encapsulated in the amorphous carrier material. However, despite not being in the form of a crystalline salt, which is usually present in the case of a typical solid mixture and / or powder composition, the composition of the present invention may lose little to no chemical stability of its active ingredient under the storage conditions mentioned herein.
[0131] The amount of active ingredient that can be used in a single dose of the composition of the present invention should be sufficient to exert its pharmacological effect. For the composition of the present invention that is administered transmucosally (e.g., sublingually, bucally, and especially intranasally), the amount should not exceed about 100 mg in a single dose. The actual dose of the relevant active ingredient mentioned above is known in the art and can be found in Martindale-The Complete Drug Reference, 40 th The drugs in question have been described in the medical literature, such as The American Journal of Clinical Chemistry, Vol. 13, No. 1, 2011, pp. 1171-1175, 2012 Edition, Pharmaceutical Press, London (2020) and documents cited therein, the relevant disclosures of all of which are incorporated herein by reference. However, the compositions of the present invention may be found to exhibit better bioavailability and / or rapid absorption, resulting in a more rapid onset of action and / or higher plasma concentrations, as compared to prior art compositions containing the same active ingredient.
[0132] In this respect, the pharmacologically appropriate amount of the active ingredient in the composition of the present invention may be less than the amount mentioned in the literature (see above).Nevertheless, such amount can be determined by a person skilled in the art and may vary depending on the type and severity of the condition being treated and what is most suitable for an individual patient.This is also likely to vary depending on the nature of the formulation and the type and severity of the condition being treated, as well as the age, weight, sex, renal function, hepatic function and response of the particular patient being treated.
[0133] Depending on the potency of the active ingredient and the final dosage form used, the total amount of active ingredient that may be used in the compositions of the present invention may range from about 0.0002% by weight, such as about 0.01% by weight, including about 0.1% by weight (e.g., about 1%, about 2% by weight or about 5% by weight), about 0.001% by weight, such as about 10% by weight (e.g., about 20% by weight), up to about 95% by weight, such as about 75% by weight, for example about 50% by weight, for example about 40% by weight, based on the total weight of the composition. This is independent of the number of separate doses (which must be the same) of the composition initially present in the dosage means according to the present invention.
[0134] For transmucosal administration, including pulmonary, buccal, sublingual, or preferably intranasal, suitable doses of active ingredient (calculated as free acid / base) per kg of body weight range from about 1 μg / kg, such as about 2 μg / kg, including about 3 μg / kg, about 5 μg / kg, or about 6 μg / kg, up to about 15 μg / kg, such as about 13 μg / kg, including about 12 μg / kg, such as about 10 μg / kg or about 8 μg / kg.
[0135] Alternatively, a suitable dose of active ingredient (calculated as free acid / base) per unit dosage is in the range of about 1 μg (e.g., about 10 μg, such as about 250 μg) to about 100 mg (e.g., about 80 mg), such as about 1 mg to about 60 mg (e.g., about 3 mg to about 50 mg, such as about 10 mg), depending on the active ingredient used.
[0136] When administered transmucosally, including pulmonary, buccal, sublingual, or preferably intranasally, specific doses of adrenaline range from about 0.1 mg (e.g., about 0.5 mg) to up to about 10 mg, such as up to about 5 mg, including up to about 3 mg or up to about 2 mg (e.g., about 1.2 mg, about 1 mg, or about 1.5 mg, including about 0.8 mg).
[0137] For other forms of administration (e.g., by injection or oral administration), a suitable dose of active ingredient (calculated as the free acid / base) per unit dosage is in the range of about 1 μg to about 500 mg (e.g., about 400 mg), such as about 1 mg to about 300 mg (e.g., about 3 mg to about 200 mg, such as about 1 mg, about 10 mg, etc.), depending on the active ingredient used.
[0138] For adrenaline and its salts, when administered via a route other than transmucosal, particular doses that may be used in the compositions of the invention (in each case calculated as the free (acid / base) compound) include about 0.1 mg to about 3 mg or about 10 mg, such as about 5 mg, including about 2 mg (e.g., about 1 mg).
[0139] As mentioned above, the composition of the present invention may also contain or be administered together with one or more alkyl sugars.In this respect, the composition of the present invention may be found to exhibit surprisingly good bioavailability and absorption rate, for example, compared to the corresponding composition that does not contain alkyl sugars and / or contains a different excipient known to act as a surfactant.
[0140] Alkyl sugars that can be used include alkyl glycosides, which are 7-18 Alkyl glycosides can be defined as any sugar attached by a linkage to an alkyl group, such as alkyl glycosides. Thus, alkyl glycosides can include alkyl maltosides (such as dodecyl maltoside), alkyl glucosides, alkyl sucrosides, alkyl thiomaltosides, alkyl thioglucosides, alkyl thiosucrose, and alkyl maltotriosides. However, it is preferred that the alkyl sugars are sugar esters.
[0141] Sugar esters that can be used in the compositions of the present invention include trisaccharide esters such as raffinose esters, monosaccharide esters such as glucose esters, galactose esters and fructose esters, and / or preferably disaccharide esters such as maltose esters, lactose esters, trehalose esters, and especially one or more sucrose esters.
[0142] The sucrose esters used in the compositions of the present invention may have a hydrophilic-lipophilic balance value of 6 to 20. The term "hydrophilic-lipophilic balance" (HLB) is a term of art that will be well understood by those skilled in the art (see, for example, 'The HLB System: A Time-Saving Guide to Emulsifier Selection' published in 1976 (revised in 1980) by ICI Americas Inc, chapter 7 (pages 20-21) of the document provides a method for determining the HLB value). The longer the fatty acid chain of the sucrose ester and the higher the degree of esterification, the lower the HLB value. The preferred HLB value is 10 to 20, more preferably 12 to 20.
[0143] Therefore, sucrose esters have the C 8-22 Saturated or unsaturated fatty acid esters, preferably saturated fatty acid esters, preferably C 10-18 Fatty acid esters, most preferably C 12 Fatty acid esters are included. Particularly suitable fatty acids from which such sucrose esters can be formed include erucic acid, behenic acid, oleic acid, stearic acid, palmitic acid, myristic acid and lauric acid. A particularly preferred such fatty acid is lauric acid. Commercially available sucrose esters include those sold under the trademarks Surfhope® and Ryoto® (Mitsubishi-Kagaku Foods Corporation, Japan).
[0144] The sucrose ester may be a diester or monoester of a fatty acid, preferably a monoester such as sucrose monolaurate. Those skilled in the art will understand that the term "monolaurate" refers to a monoester of lauric acid, and that the terms "lauric acid ester" and "laurate" have the same meaning and can therefore be used interchangeably. Commercially available sucrose monolaurate products are sometimes referred to as "sucrose laurate". Commercially available sucrose monolaurate (or sucrose laurate) products, such as Surfhope® D-1216 (Mitsubishi-Kagaku Foods Corporation, Japan), may contain small amounts of diesters and / or higher sucrose esters, as well as small amounts of other sucrose esters and free sucrose, and are suitable for use in the present invention. Those skilled in the art will understand that any reference herein to a particular sucrose ester includes commercially available products that contain that sucrose ester as a major component.
[0145] Preferred sucrose esters contain only one sucrose ester, which means that a single sucrose ester (e.g., a commercially available sucrose ester product) contains a single sucrose ester as the main component (commercial products may contain impurities, e.g., a monoester product may contain small amounts of diesters and / or higher esters, and such products may be considered to "contain only one sucrose ester" in the context of the present invention). As used herein, the term "main component" will be understood to refer to the main component (e.g., more than about 50% by weight or volume, such as about 70% by weight / weight or volume / volume) in a mixture of sucrose esters, such as a common commercially available surfactant product, which is typically sold with a certain range of ester composition.
[0146] A particularly preferred sucrose ester is sucrose monolaurate.
[0147] The amount of alkyl sugars that may be used, whether included within a composition of the invention or in a final dosage form comprising one or more compositions of the invention, may range from about 0.5% to about 5% by weight, preferably from about 0.1% to about 10% by weight, such as from about 0.75% to about 3% by weight (e.g., up to about 2% by weight, such as about 1% by weight), based on the total weight of the composition.
[0148] Furthermore, optional additional excipients may be used within or administered with the compositions of the invention, including one or more (further) surfactants. Surfactants that may be mentioned include polyoxyl 8 stearate (Myrj™ S8), polyoxyl 32 stearate (Gelucire® 48 / 16), polyoxyl 40 stearate (Myrj™ S40), polyoxyl 100 stearate (Myrj™ S100), and polyoxyl 15 hydroxystearate (Kolliphor® HS Polyoxyethylene alkyl ethers (e.g., Brij™) including polyoxyl cetostearyl ethers (e.g., Brij™ CS12, CS20, and CS25), polyoxyl lauryl ethers (e.g., Brij™ L9 and L23), and polyoxyl stearyl ethers (e.g., Brij™ S10 and S20); polyoxyglycerides (e.g., Gelucire™) including lauroyl polyoxyglyceride (Gelucire™ 44 / 14) and stearoyl polyoxyglyceride (Gelucire™ 50 / 13); sorbitan esters (e.g., Myrj™) including sorbitan monopalmitate (Span™ 40) and sorbitan monostearate (Span™ 60) (e.g., Myrj™); , Span™), polysorbates (Tweens™), including polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), and polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), and sodium lauryl sulfate; and monoacylglycerols (monoglycerides) such as 2-oleoylglycerol, 2-arachidonoylglycerol, monolaurin, glycerol monomyristate, glycerol monopalmitate, glyceryl hydroxystearate, and preferably, glycerol monostearate, glycerol monooleate (e.g., Cithrol™), and glycerol monocaprylate (e.g., Capmul™).Other surfactants may include lauryl lactate, dipalmitoyl phosphatidylcholine (DPPC), and poloxamer.
[0149] Other optional additional components (excipients) that may be included in or administered with the compositions of the invention include isotonicity and / or osmolarity agents (e.g., sodium chloride), sterols (or steroid alcohols) such as cholesterol and phytosterols (e.g., campesterol, sitosterol, and stigmasterol); antioxidants (e.g., sodium metabisulfite, or in addition, alpha-tocopherol, ascorbic acid, potassium ascorbate, sodium ascorbate, ascorbyl palmitate, butylated hydroxypropyl esters, etc.); toluene, butylated hydroxyanisole, dodecyl gallate, octyl gallate, propyl gallate, ethyl oleate, monothioglycerol, vitamin E polyethylene glycol succinate, or thymol; chelating (complexing) agents (e.g., edetic acid (EDTA), citric acid, tartaric acid, malic acid, maltol, and galactose, including any salt form of these agents); preservatives (e.g., benzalkonium chloride, or in addition, benzyl alcohol, boric acid, parabens, propionic acid, phenol, cresol, or xylitol); viscosity modifiers or gelling agents (such as cellulose derivatives including hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, etc., starch and modified starches, colloidal silicon dioxide, aluminum metasilicate, polycarbophil (e.g., Noveon®), carbomer (e.g., Carbopol®), and polyvinylpyrrolidone); mucoadhesive polymers such as carboxymethylcellulose, modified cellulose gum, and sodium carboxymethylcellulose (NaCMC); starch derivatives such as moderately crosslinked starches, modified starches, and sodium starch glycolate; acrylic polymers such as crosslinked polyvinylpyrrolidone, carbomer and its derivatives (polycarbophil, Carbopol®, etc.); polyethylene oxide (PEO); chitosan (poly-(D-glucosamine)); natural polymers such as gelatin, sodium alginate, pectin; scleroglucan; xanthan gum; guar gum; polyco-(methyl vinyl ether / maleic anhydride); and croscarmellose (e.g., croscarmellose sodium);pH buffers (e.g., citric acid, maleic acid, malic acid, or glycine or their corresponding salts such as sodium citrate); colorants; penetration enhancers (e.g., isopropyl myristate, isopropyl palmitate, pyrrolidone, or tricaprylin); other lipids (neutral and polar); aromatic carboxylic acids such as benzoic acid, e.g., toluic acid or salicylic acid, optionally substituted with one or more groups selected from methyl, hydroxyl, amino, and / or nitro; optionally, flavors (e.g., lemon, peppermint powder, or preferably menthol), sweeteners (e.g., neohesperidin, acesulfame K, or sucralose), and dyes. Other excipients may include trisaccharides (e.g., raffinose) and mannitol, and pH adjusters (e.g., hydrochloric acid and sodium hydroxide);
[0150] The total amount of such "additional" excipients (including non-alkyl sugar surfactants that may be present in the compositions of the invention) that may be included within the compositions of the invention themselves (regardless of the form in which they are included) may be up to about 15% by weight, such as up to about 5% by weight (e.g., about 10% by weight), based on the total weight of the composition.
[0151] The total amount of such "additional" excipients that may be included in a final dosage form comprising one or more compositions of the present invention may be up to about 99%, such as up to about 99.99%, including up to about 90%, for example, when the one or more additional excipients are fillers or carriers for tablets, films, etc.
[0152] Those skilled in the art will understand that if any additional optional ingredients are included in the composition of the present invention, the nature of those ingredients and / or the amount of those ingredients included must not adversely affect the Tg of the composition for the reasons mentioned above. In this regard, such optional ingredients can be incorporated into the spray drying process (i.e., mixed together with the active ingredient and carrier material(s) in a suitable volatile solvent and then spray dried) or can be included separately in the spray dried particles.
[0153] In particular, taking into account the increased chemical stability that the compositions of the invention pose for highly unstable active ingredients such as adrenaline, and the fact that the compositions of the invention are primarily intended for use in the treatment of patients who are prone to allergic reactions (and therefore may be sensitized to certain chemicals), it is preferred that the compositions of the invention are essentially free of such "additional" excipients, in particular the above-mentioned antioxidants and / or preservatives such as benzalkonium chloride, more in particular sulfites, and / or chelating agents such as EDTA.
[0154] In this regard, the compositions of the present invention may consist essentially of a pharmacologically effective dosage of an adrenergic receptor modulator or salt thereof, a pharma- ceutically acceptable carrier material as defined herein (i.e., maltodextrin as defined herein, and optionally a co-carrier material such as a disaccharide), and (optionally) an alkyl sugar material as defined herein. When the compositions of the present invention "consist essentially" of the above components, this will be understood to mean that the composition includes only those components, together with other features and / or components that do not substantially affect the basic and novel characteristic(s) of the composition. Alternatively, in the situation where the compositions / dosage forms of the present invention "consist essentially" of those components of the present invention, this may be understood to mean that the composition includes at least about 90% by weight of those components, including at least about 95% by weight, including at least about 97% by weight (e.g., about 99% by weight or even about 99.9% by weight).
[0155] According to a further aspect of the present invention there is provided a composition of the invention for use in medicine (human and veterinary medicine), thus for use in the treatment of a patient in need of medical treatment of a condition which the associated active ingredient is known to treat.
[0156] "Treatment" of such conditions includes curative, symptomatic and palliative treatment as well as prophylaxis / prevention or diagnosis of such conditions.
[0157] Thus, the compositions of the present invention are useful in the treatment of various disorders depending on the active ingredient(s) contained in such compositions.
[0158] The compositions of the invention containing dopamine may be used in the correction of hemodynamic imbalances present in shock syndromes resulting from myocardial infarction, trauma, endotoxin sepsis, open heart surgery, renal failure, and chronic heart failure (congestive failure), the compositions of the invention containing oxymetazoline may be used as a decongestant, the compositions of the invention containing dobutamine may be used, for example, in the treatment of heart failure, the compositions of the invention containing mirabegron may be used in the treatment of overactive bladder syndrome, and the compositions of the invention containing bronchodilators such as albuterol (salbutamol), formoterol, levalbuterol, olodaterol, salmeterol, and terbutaline may be used in the treatment of asthma (exercise-induced bronchospasm (EIB)), and / or chronic obstructive pulmonary disease (COPD, including associated bronchospasm). The compositions of the invention containing terbutaline may also be used in the treatment of preterm labor.
[0159] The compositions of the invention containing norepinephrine may be used in blood pressure control (and / or cardiac arrest) induced in certain acute hypotensive conditions, including sympathectomy, poliomyelitis, pheochromocytectomy, spinal anesthesia, myocardial infarction, sepsis, blood transfusion, or drug reactions. The compositions of the invention containing isoprenaline may be used in the treatment of bradycardia, heart block, and in some cases asthma.
[0160] In particular, the compositions of the present invention comprising adrenaline are useful in treating allergic reactions, including, for example, heart failure (e.g., heart attack) and / or more particularly, extreme or severe allergic reactions, anaphylaxis, and / or anaphylactic shock, characterized by, for example, a severe drop in blood pressure, as a result of, for example, insect stings / bites, food, drugs, and / or other substances. Extreme and / or severe allergic reactions may further include sepsis and / or septic shock, which may be, for example, a reaction to infection by fungi, bacteria, and / or viruses. Anaphylaxis and sepsis may further result in organ dysfunction, including organ failure and / or eventual death.
[0161] The compositions of the invention comprising adrenaline are also useful in treating, for example, any type 1 hypersensitivity reaction, particularly allergic asthma, allergic conjunctivitis, allergic rhinitis, anaphylaxis (including idiopathic or exercise-induced anaphylaxis), angioedema, urticaria, eosinophilia, drug allergies (including antibiotic allergies), food allergies, allergies to animal sera, insect bites and stings, diagnostic test substances, and other allergens; treating acute asthma attacks to relieve bronchospasm; treating systemic toxic responses (anaphylactoid reactions); paroxysmal alterations of the heartbeat mechanism. These compounds are useful in the treatment and prevention of episodes of transient atrioventricular block with cardiac arrest and / or fainting, including transient loss of consciousness due to a sudden but significant decrease in cardiac output caused by hypertension (Stokes-Adams syndrome); inducing an increase in mean arterial blood pressure in adult patients with hypotension associated with septic shock; inducing and maintaining pupillary dilation during intraocular surgery; in the treatment of gastrointestinal and / or renal bleeding; in the treatment of superficial bleeding, premature labor, hypotension, and cardiogenic, hemorrhagic, and traumatic shock; and / or in the treatment of croup (an infection of the upper respiratory tract that obstructs breathing and causes a characteristic barking cough).
[0162] The compositions of the invention comprising adrenaline are particularly useful in the treatment and / or prevention (prophylaxis) of severe reactions, including anaphylaxis and sepsis and / or anaphylactic and septic shock as described above. Prevention and / or prophylaxis of these severe reactions may be achieved by administration (including self-administration) of one or more compositions of the invention to a patient at risk of such reactions following exposure (or suspected exposure) to the relevant substances described above, to which the patient is sensitive and / or sensitized.
[0163] According to three further aspects of the invention there is provided: A composition of the invention comprising an adrenaline receptor modulator (e.g., adrenaline) or a pharma- ceutically acceptable salt thereof for use in the treatment of an allergic reaction (e.g., by transmucosal, such as intranasal, administration of the composition); Use of a composition of the invention comprising an adrenaline receptor modulator (e.g., adrenaline) or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an allergic reaction (e.g., transmucosal, such as intranasal), and A method for treating an allergic reaction, the method comprising administration (e.g. transmucosally, such as intranasally) of a composition of the invention comprising an adrenergic receptor modulator (e.g., adrenaline) or a pharma- ceutically acceptable salt thereof to a patient suffering from or susceptible to the condition.
[0164] 1. A method for treating an allergic reaction in a human patient, comprising: (a) identifying a human patient who is suffering from or at risk for an allergic reaction; (b) administering an adrenoceptor modulator (e.g., adrenaline) or a pharma- ceutically acceptable salt thereof, in the form of a composition of the invention, to a body cavity of the patient that contains a mucosal surface in a dose suitable for treating the allergic reaction, and presenting the composition to the mucosal surface to promote absorption of the adrenoceptor modulator or salt thereof across the mucosal surface to treat or prevent the allergic reaction.
[0165] The compositions of the present invention may be administered by any suitable dosing means known to those skilled in the art. The compositions of the present invention may be administered transmucosally, in particular intranasally, by means of a suitable nasal applicator or dispenser, which is capable of administering a suitable dose of the active ingredient in the form of one or more compositions of the present invention to the nasal cavity.
[0166] Thus, a suitable nasal dosing means and / or applicator can contain and store one or more doses of the composition of the invention itself, or can be attached to a reservoir / container that contains and stores one or more doses of said composition of the invention and prevents significant loss of the physical and chemical integrity of the composition, including through ingress of water. In this way, the composition is ready for use as soon as the applicator device is actuated by the end user (whether this is for single or multi-dose use), whereupon the applicator delivers a composition (e.g., a powder) having an appropriate dose of the active ingredient as defined herein to the nasal mucosa of the subject.
[0167] Suitable applicator means have been described in the prior art. When used with the compositions of the present invention, such compositions may be loaded into a reservoir attached to or forming part of such applicator means and are contained therein until the applicator means, or dispenser, is actuated. Hereinafter, the terms "applicator", "dispensing device", "device", "applicator means", "dispensing means", "applicator device", "dispensing device" and "inhaler" may be used interchangeably and may mean the same thing.
[0168] Due to the unexpected stability of the compositions of the present invention, there is no need to inspect the contents of the reservoir (i.e., the powder composition) prior to administration or use. This is in contrast to commercially available devices such as the EpiPen, whose product labels include the requirement to check the integrity of the contents prior to dispensing for very good reasons including the instability of the liquid solution composition contained therein to heat, cold, and light.
[0169] With this in mind, the reservoir containing the composition of the present invention may be opaque, which will be understood by those of skill in the art to include "not transparent or translucent, not allowing light to pass through and / or not allowing light to pass through."
[0170] Thus, an applicator comprising a composition of the present invention does not include (or require) an inspection window through which the contents of the applicator's reservoir can be observed, and in this regard, may be completely opaque in character, i.e., at least about 98%, such as at least about 99%, particularly about 99.9% opaque, and / or about 2% or less, such as about 1% or less, particularly about 0.1%, transparent, translucent, and / or light transmissible, allowing inspection of the contents of the reservoir.
[0171] Such applicator means may therefore also include a mechanism for expelling the powder composition described herein from the reservoir via an outlet (or dispensing) means, including a suitably shaped nozzle or the like, any size sized for placement in a human body cavity, such as a nostril.
[0172] Thus, the mechanism for expelling the powder may include means for actuating the device, which may include breath-actuated actuation, or may include actuation means for generating a force upon actuation of the device by a user.
[0173] Therefore, the applicator needs to be able to provide a reproducible and sufficient amount of the powder formulation in a single administration step that provides a therapeutic dose of the active ingredient (and in a manner that does not require "priming" the device).
[0174] Moreover, due to the unexpected stability of the compositions of the present invention, and the lack of need to test the contents of the reservoir (i.e., powder composition) prior to administration use, the applicator may be used to administer adrenaline or a pharma- ceutically acceptable salt thereof to a mucosal surface to treat or prevent said allergic reaction as soon as a patient is identified as exhibiting symptoms of, or at risk of, an allergic reaction. Thus, the administration step identified above may be performed immediately following the steps identified above, without any delay, which delay may be (i) testing a composition of the invention; and (ii) A period of time sufficient to determine whether the relevant composition can be safely administered to a patient to effectively treat the allergic reaction.
[0175] Nasal applicators / inhalation devices that may be used to administer the compositions of the present invention in the form of a powder may include metered dose inhalers (MDIs), dry powder inhalers (DPIs; including low, medium, and high resistance DPIs) and multi-dose applications such as soft mist inhalation devices (SMIs), which may be adapted based on techniques known in the art of delivery of active ingredients to the lungs.
[0176] In an MDI, the compositions of the present invention can form a stable suspension when suspended in a solvent, such as a propellant typically used therein, which must have sufficient vapor pressure to form an aerosol upon actuation of the delivery device (e.g., a hydrocarbon, a fluorocarbon, a hydrogen-containing fluorocarbon, or a mixture thereof).
[0177] However, when the nasal applicator is a single-dose applicator in which the composition is dispensed after actuation and discarded after use, suitable applicator means or devices for delivering a single dose of the active ingredient include breath-assisted and blow-assisted devices (such as Optinose®), as well as those described in US 6,398,074, US 6,938,798, or US 9,724,713, the relevant disclosures of all documents are incorporated herein by reference. Figures 1 and 2 of the present application are based on Figures 1 and 2 of US 6,398,074, respectively, and Figures 3-7 are based on Figures 19-23 of US 9,724,713, respectively. Both are diagrams of applicators that can be used to intranasally administer the composition of the present invention.
[0178] In Figure 1, the device comprises a body top / dispenser head 1 incorporating an outlet channel 40 (i.e. part of the "outlet means" mentioned above) and a gripping means 60 enabling the user to actuate the device. On the inside of the body top / dispenser head 1 is attached an element, the assembly of which is designated by the reference number 2, which incorporates a reservoir 10 and an air chamber 22 for the air blast 20. This element 2 can be produced integrally with the body 1. A body bottom 3 is also provided to be able to slide relative to the body top 1 and relative to the element 2, on which the user exerts a pressure force to actuate the device.
[0179] The reservoir 10 contains a single dose of the composition of the invention. The reservoir 10 has an air inlet 11 and a product outlet 15. A product retention device 12, including an air permeable grid, is positioned within the air inlet 11 for retaining the product within the reservoir 10 until the composition is dispensed. The product outlet 15 is blocked, preferably in a sealing manner, by a closure ball 16, which is removed from its blocking position by the flow of air when the applicator is actuated and the product is dispensed.
[0180] When the user actuates the device, pressure is applied to the plunger 25 such that the piston 21 compresses the air 20 contained in the chamber 22. As the grid 12 is permeable to air, the compression of the air in the chamber 22 creates an air blast which is transmitted to the reservoir 10 and thus to the closing ball 16 blocking the product outlet 15.
[0181] The dimensions of the closure ball 16 and its fixation at the reservoir product outlet 15 are such that when a minimum predetermined pressure is created through the reservoir 10 by a blast of air 20, the ball 16 is removed from its blocking position.
[0182] The pre-compression created by the closing ball 16 ensures that when the ball is removed from its blocking position, the energy stored in the user's hand is such that the piston 21, integral with the plunger 25, is propelled within the chamber 22, thereby generating a powerful blast of air 20, i.e. an airflow suitable for finely atomizing a dose of the composition of the invention.
[0183] Once this minimum pressure is reached, the ball moves rapidly towards the outlet channel 40 of the device and the flow of air 20 created by the blast expels substantially all of the dose of the composition of the present invention contained within the reservoir 10.
[0184] Preferably, the outlet channel 40 has a diameter larger than that of the closing ball 16, to allow the dose of product to be discharged through the outlet channel 40 by flowing around the ball 16. As shown in Figure 2, which represents the same device after actuation, the channel 40 is provided with means 41 for stopping or fixing the ball 16, to prevent the discharge of the ball from the device when the product is being discharged.
[0185] Further embodiments that can be used to administer the compositions of the invention intranasally are provided in column 7, line 50 to column 8, line 61 and Figures 19 to 23 of US 9,724,713, which are reproduced as Figures 3 to 7 in the present application.
[0186] In this embodiment, the reservoir 10 is fixed within a body top / dispenser head 1 which includes a dispenser outlet channel 40 (i.e., part of the "outlet means" previously discussed) having a gripping means or finger rest 60 which allows a user to actuate the device. A radial shoulder 37 (see Figure 5) of the body top / dispenser head 1 advantageously defines an assembly location for the reservoir 10 within the body top / dispenser head 1.
[0187] The mechanical opening system comprises a set of rods 61, 62, and when the device is actuated, a second rod portion 62 is pushed against said first rod portion 61. At the end of their actuation stroke, i.e. in the dispensing position, the set of rods 61, 62 cooperate with the closure element 16, which is spherical, in particular a ball as in the first embodiment discussed above, and mechanically eject it from the closed position.
[0188] In this embodiment, the piston 21 is separate from the first rod portion 61 and slides against both the air chamber 22 and a cylindrical surface 614 fixed to the first rod portion 61. Figure 7 is a perspective view of the air expeller of the device of Figures 3-6 in a rest position.
[0189] The air chamber 22 may thus be cylindrical and in a rest position communicate with the surrounding air by means of flutings or grooves 615 formed in said cylindrical surface 614 and cooperating with the piston 21 in particular in the rest position. The piston 21 thus comprises an inner lip 215 which slides in an airtight manner on the cylindrical wall 614 during actuation and which cooperating with said flutings 615 in the rest position. The piston 21 also comprises an axial extension 216 which cooperating with an upper edge 251 of a pusher element 25 (called "plunger" in the first embodiment) which moves said piston 21 in the air chamber 22 during actuation.
[0190] The retaining member 42 is extended downwardly by an axial extension 43 which contacts an upper axial end 610 of the first rod portion 61 during actuation.
[0191] Additionally, in this embodiment, there is no outer body, only a cover 27 assembled onto the lower axial edge of the air chamber 22 .
[0192] A spring 80 is provided between the radial flange 225 of the air chamber 22 and the first rod portion 61 and the portion forming the cylindrical surface 614 so that the air expeller automatically returns to its rest position after actuation.
[0193] The principle of operation is as follows: In the rest position of Fig. 3, the reservoir 10 is sealed closed by the retaining member 42 and the closure element / ball 16. The air expeller is open to the atmosphere by cooperation between the inner lip 215 of the piston 21 and the flutings 615 of the cylindrical surface 614.
[0194] When it is desired to actuate the device, the user pushes the pusher element 25. During this first stroke, the inner lip 215 of the piston leaves the flutings 615 and comes into air-tight cooperation with the cylindrical surface 614, thereby closing the air chamber 22. At the same time, the upper edge 251 of the pusher element 25 comes into contact with the axial extension 216 of the piston 21 and the upper axial end 610 of the first rod portion 61 comes into contact with the axial extension 43 of the retaining member 42.
[0195] However, as can be seen in FIG. 4, the upper axial end 621 of the second rod portion 62 is still not in contact with the rounded surface 55 of the closure element / ball 16 .
[0196] Continued actuation therefore simultaneously moves the piston 21 within the air chamber, thereby compressing the air contained therein and moving the retaining member 42 away from the position that closes the reservoir 10. When the second rod portion 62 contacts the rounded surface 55 of the closure element / ball 16, said closure element / ball is mechanically expelled from its closed position so that the composition can be expelled under the influence of the air compressed by the air expeller.
[0197] The dispensing position is shown in Figure 5. As can be seen in Figure 5, the retaining member 42 can move away from the first rod part 61 while the composition is being expelled under the effect of compressed air provided by the air expeller. In this position, the closure element / ball 16 is expelled from the reservoir 10 so that fluid or powder can be dispensed under the effect of compressed air. The closure element / ball 16 is thus jammed in the spline 3 of the top body / dispenser head 1, which in particular prevents any risk of the closure element / ball 16 being expelled from the top body / dispenser head 1.
[0198] As shown in FIG. 6, when the user releases the device, the spring 80, which was compressed during actuation, returns the first rod portion 61 towards its rest position. This creates a suction force that draws the closure element 16 and the retaining member 42 towards or near their closed position. This therefore blocks a new suction path, with the empty reservoir remaining assembled on the air expeller so that it does not get dirty during its automatic return to the rest position. However, the piston 21 remains in its dispensing position as a result of friction with the air chamber 22 and the suction force created in the reservoir 30, such that the cylindrical surface 614 slides on the inner lip 215 until said inner lip once again cooperates with the flutings 615. At this point, the air chamber 22 is again in communication with the surrounding air and the suction force by returning to the rest position is no longer created. The piston 21 is therefore also retracted towards its rest position. This allows the reservoir to be closed after use.
[0199] Optionally, the unit formed by the body top / dispenser head 1 and the empty reservoir 10 can be removed from the air expeller and replaced with a new unit containing a full reservoir.
[0200] Suitable applicator devices that can be used include those available from Aptar Pharma, France (UDS Monopowder). See, for example, International Patent Applications Nos. 2022 / 208014 and 2021 / 005311. Other examples of applicator devices that can be used in combination with the compositions of the present invention (especially those in the form of powders) include those described in U.S. Patent Application Nos. 2011 / 0045088, 7,722,566 (see, for example, Figures 1 and 7) and 5,702,362, and International Patent Application No. 2014 / 004400, the relevant disclosures of which are incorporated herein by reference.
[0201] According to a further aspect of the present invention, there is provided a process for manufacturing an applicator device comprising a composition of the present invention, the process comprising the step of loading the composition into a reservoir within or associated with the applicator device.
[0202] According to a further aspect of the present invention there is provided a needleless applicator suitable for administering a solid amorphous single particle powder composition of the present invention to a body cavity of a human patient, the cavity comprising a mucosal surface, the applicator comprising: (i) a reservoir (optionally opaque) within or associated with said applicator that contains a composition of the present invention; (ii) optional actuation means for generating a force upon actuation of the device by a user; and (iii) a dispensing means through which the powder composition may be dispensed after said actuation.
[0203] The term "needle-free" refers to a device for administering a pharmaceutical active ingredient that does not include an injection means that further includes a means for piercing, e.g., the skin or a mucosal surface, to inject said active ingredient into the body, e.g., subcutaneously or intramuscularly (as the adrenaline auto-injector mentioned above does).
[0204] According to another aspect of the present invention there is provided an applicator and / or dispenser device comprising one or more compositions of the present invention in powder form, which applicator or device may be actuated one or more times to deliver one or more compositions of the present invention, each containing an appropriate dose of active ingredient on each such actuation, the applicator / dispenser device comprising: an outlet through which at least one composition is dispensed; a means for generating an external force (e.g., airflow) upon actuation of the device by a user; At least one (optionally replaceable, optionally opaque) reservoir containing one or more compositions of the present invention, in or capable of being placed in direct or indirect communication with a dispenser outlet; a replaceable, optionally reversible, sealing means in the device and / or reservoir to retain one or more compositions within the reservoir until the composition is dispensed; a mechanical opening system which cooperates with said sealing means such that the unitary composition of the present invention is mechanically expelled by the force application means when the device is actuated; Optionally, a mechanism for resealing the device and / or the reservoir to retain the further composition within the reservoir until the further composition is dispensed.
[0205] According to a still further aspect of the present invention there is provided an applicator and / or dispenser device containing a unit dose of the composition of the present invention and suitable for dispensing the composition, the applicator / dispenser device comprising: Dispenser outlet, an air expeller for generating an air flow while the device is actuated, the air expeller including a piston that slides within the air chamber between a rest position and a dispensing position; The piston slides in an airtight manner within the air chamber; at least one (e.g., opaque) reservoir containing a dose of the composition of the present invention, the reservoir comprising an air inlet connected to the air expeller; a composition outlet connected to the dispenser outlet; said air inlet including a displaceable sealing means (e.g., a retaining member) for retaining the composition within the reservoir until the composition is dispensed; a composition outlet of the reservoir, said composition outlet being closed by a closure element fitted to said composition outlet; the device further comprising a mechanical opening system cooperating with the closure element to mechanically eject the closure element from the closed position during actuation of the device; and The piston of the air expeller cooperates in a non-airtight manner with the air chamber when in a rest position.
[0206] In the latter aspect of the invention, it is preferred that: (i) the air chamber into which the piston slides in an airtight manner is substantially cylindrical; (ii) the closure element is press-fitted onto the composition outlet of the reservoir; (iii) the air chamber is in communication with the atmosphere in a stationary position; and / or (iv) the piston includes an inner lip adapted to cooperate with a cylindrical surface, the cylindrical surface including fluting that cooperates in a non-sealing manner with the inner lip of the piston in a rest position.
[0207] Such nasal applicators or dispensing devices can provide a suitable and reproducible powder spray pattern and / or geometric plume shape that allows efficient delivery of the powder to the nasal cavity (e.g., nostrils).
[0208] In the composition of the present invention, the average particle size can be presented as the average diameter by weight, number, or volume. As used herein, the term "average diameter by weight" is understood by those skilled in the art to include that the average particle size is characterized and defined from the particle size distribution by weight, i.e., the existing fraction (relative amount) in each size class is defined as the weight fraction obtained, for example, by sieving (e.g., wet sieving). The term "average diameter by volume" is similar in meaning to the average diameter by weight, but is understood by those skilled in the art to include that the average particle size is characterized and defined from the particle size distribution by volume, i.e., the existing fraction (relative amount) in each size class is defined as the volume fraction measured, for example, by laser diffraction. As used herein, the term "average diameter by number" is understood by those skilled in the art to include that the average particle size is characterized and defined from the particle size distribution by number, i.e., the existing fraction (relative amount) in each size class is defined as the number fraction measured, for example, by microscopy. Other instruments known in the art may be used to measure particle size, such as, for example, instruments sold by Malvern Instruments, Ltd (Worcestershire, UK), Sympatec GmbH (Clausthal-Zellerfeld, Germany), and Shimadzu (Kyoto, Japan).
[0209] Where the compositions of the invention are formulated, for example, for administration orally, topically, to the buccal, ocular or other mucous membrane, or by injection or infusion, particle size is not (or may even be) critical, but powder compositions of the invention typically have a volumetric mean diameter (VMD) within the range of about 0.2 μm, such as about 0.5 μm (e.g., about 1 μm), up to about 1,000 μm (e.g., up to about 500 μm, such as about 400 μm or about 500 μm), and appropriate particle size ranges may be selected based on the dosage form intended to contain such compositions.
[0210] However, one of ordinary skill in the art will appreciate that to allow for effective intranasal administration, the powder will typically have a volumetric mean diameter (VMD) in the range of about 5 μm up to about 300 μm (e.g., up to about 200 μm). Depending on the applicator device used, the VMD may range from about 10 μm to about 100 μm, such as from about 20 μm to about 60 μm.
[0211] Preferred particle size distributions for intranasal drug delivery may also include those with D10 greater than about 3 μm, such as greater than about 10 μm, and less than about 75 μm (e.g., up to about 50 μm), and D90 between about 80 μm and about 1,000 μm, such as less than about 100 μm (e.g., about 500 μm). One of ordinary skill in the art will appreciate that the parameter "D10" (or "Dv(10)") refers to the size (or diameter) in the particle size distribution below which 10% of the total volume of the material in the sample falls. Similarly, "D90" (or "Dv(90)") refers to the size below which 90% of the material falls.
[0212] Powders having a particle size distribution and VMD within the above ranges include the bulk VMD and / or the emitted VMD, i.e., the particle size distribution when initially loaded into and / or expelled from the device, respectively.
[0213] Particle size can be measured by standard equipment such as dry (or wet) particle size measurement techniques, including dry dispersion techniques available from manufacturers such as Sympatec and Malvern.
[0214] Preferred particle shapes include spherical or substantially spherical, meaning that the particles have an aspect ratio of less than about 20, more preferably less than about 10, such as less than about 4, and especially less than about 2, and / or may have a variation in radius (measured from the center of gravity to the particle surface) of less than about 50% of the mean value, such as less than about 30% of the mean value, for example less than about 20% of that value, in at least about 90% of the particles.
[0215] Nevertheless, the particles may be of any shape, including irregularly shaped (e.g., "raisin" shaped), needle-shaped, disk-shaped, or rectangular shaped particles. For non-spherical particles, size may be given as the diameter of a corresponding sphere of, for example, the same weight, volume, or surface area.
[0216] The spray angle of the powder compositions of the present invention upon emission (dispensing) from a nasal applicator and / or dispenser device should preferably be less than about 90°.
[0217] When the word "about" is used herein in the context of quantities, such as absolute amounts, e.g., doses, weights, volumes, sizes, diameters, aspect ratios, angles, or relative amounts (e.g., percentages) of individual components in a composition or of a component of a composition (including concentrations and ratios), time frames, and parameters such as temperature, pressure, relative humidity, etc., it will be understood that such variables are approximate and thus may vary by ±10%, e.g., ±5%, and preferably ±2% (e.g., ±1%) from the actual numerical values specified herein. This is true even when such numbers are first presented as percentages (e.g., "about 10%" may mean ±10% for the number 10, which is anywhere from 9% to 11%).
[0218] The compositions of the present invention have the advantage that they can be stored over a wide range of temperatures and / or relative humidity. Thus, the compositions of the present invention can be subjected to low temperatures (e.g., below freezing) without affecting the amount of active ingredient administered to a subject. Furthermore, applicators containing the powder compositions of the present invention can have the advantage that these compositions are physically and chemically stable at all (higher) temperatures than the formulations contained in related prior art devices such as EpiPen.
[0219] The compositions of the present invention may further have the advantage of providing a higher bioavailability of the active ingredient compared to prior art compositions, such as compositions containing adrenaline. The compositions of the present invention may provide this higher bioavailability along with more rapid absorption, which is likely to result in a more rapid onset of action than such prior art and / or commercially available compositions, thus fulfilling an important medical need.
[0220] The applicators, compositions, pharmaceutical formulations, uses, and methods described herein may also have the advantage that they may be more convenient for first responders, physicians, and / or patients, may be more effective, may have less toxicity, may have a broad spectrum of activity, may be more potent, may produce fewer side effects, may have less inter-patient variability, or may have other useful pharmacological properties over similar formulations or methods (treatments) known in the prior art, whether for use in treating a condition for which the associated active ingredient is known, by transmucosal administration, such as intranasally, or otherwise, in treating said condition.
[0221] The invention is illustrated by the following examples, but is in no way limited, with reference to the drawings in which Figs. 1-7 represent drawings of an actuator device that may be used to dispense the powder composition, and Fig. 8 shows epinephrine plasma concentrations versus time (linear scale, arithmetic mean) by treatment obtained in a Phase I clinical study. [Brief description of the drawings]
[0222] [Figure 1] FIG. 1 depicts a diagram of an actuator device that may be used to dispense a powder composition. [Diagram 2] FIG. 2 depicts a diagram of an actuator device that may be used to dispense a powder composition. [Diagram 3] FIG. 3 depicts a diagram of an actuator device that may be used to dispense a powder composition. [Figure 4] FIG. 4 depicts a diagram of an actuator device that may be used to dispense a powder composition. [Diagram 5] FIG. 5 depicts a diagram of an actuator device that may be used to dispense a powder composition. [Figure 6] FIG. 6 depicts a diagram of an actuator device that may be used to dispense a powder composition. [Figure 7] FIG. 7 depicts a diagram of an actuator device that may be used to dispense a powder composition. [Figure 8] FIG. 8 shows epinephrine plasma concentrations versus time (linear scale, arithmetic mean) by treatment obtained in a Phase I clinical study.
[0223] Comparative Example 1 Spray-dried epinephrine (adrenaline) formulation Adrenaline bitartrate (0.729 g; Fisher Scientific, Sweden) was dispensed into a glass flask (total 2.50 g) together with α-D-lactose monohydrate (0.500 g; DFE Pharma, Germany), maltodextrin (Glucidex IT 12DE, 1.247 g, Roquette, France), and sucrose monolaurate D-1216 (0.025 g, Mitsubishi-Kagaku Foods Corporation, Japan) and dissolved in MQ water (47.50 g) by stirring at room temperature.
[0224] The resulting mixture was fed into a spray dryer (ProCepT, Belgium) equipped with an ultrasonic nozzle operating at 25 kHz. The feed rate of the spray dryer was set at 3.0 g / min, the inlet temperature was set at 180° C., the gas flow rate was set at 300 L / min, and the cyclone gas was set at 1.5 bar.
[0225] The resulting spray dried powder was collected fine, dry, free-flowing, with a nominal dosage of 4 mg adrenaline free base in 25 mg powder.
[0226] Powders were analysed for particle size distribution (PSD) by dry powder laser diffraction. Samples were dispersed in an Aero S dry dispersion unit (using 0.5 bar compressed air) before sizing with a Mastersizer3000 laser diffraction sensor (both from Malvern Panalytical, UK) as shown in Table 1 below. [Table 1]
[0227] The PSD of the adrenaline formulation was well within a range of distribution suitable for intranasal administration.
[0228] The assay and purity of the spray dried adrenaline formulation was determined by HPLC / UV analysis: the assay was 99.7% and the percentage of total related substances (RS%) (i.e., impurities and degradation products) was less than 0.29%.
[0229] Comparative Example 2 Chemical stability of spray-dried powders Amounts of 105-115 mg of the spray-dried powder from Comparative Example 1 above were dispensed into 1.5 mL glass vials closed with screw caps. Two vials were placed in a climate cabinet at 40° C. and 75% relative humidity (40 / 75) and two vials were placed in a climate cabinet at 25° C. and 60% relative humidity (25 / 60). For each storage condition, one vial was left in the cabinet as is and one vial was packaged in a heat-sealed aluminum pouch.
[0230] The chemical stability of the drug substance after up to 18 months is summarized for different compositions and packages in Table 2 below, along with the total amount of impurities and degradation products expressed as RS%, where NA means "not analyzed". [Table 2]
[0231] Comparative Example 3 Pharmacokinetic study of adrenaline in dogs after intranasal and intramuscular administration. The objective of this study was to obtain and evaluate the baseline pharmacokinetic profile following intranasal administration of the composition of Comparative Example 1 and following intramuscular administration of adrenaline in aqueous solution.
[0232] The study was conducted on six beagle dogs, three males and three females, approximately 15-18 months of age. The dogs were dosed in a crossover dosing regimen to compensate for potential sequential effects. Dosing was always performed in the morning, and the dogs were fasted overnight (minimum 8 hours). Water was available ad libitum, and food was offered 4 hours after dosing.
[0233] Each dog was administered intranasally the composition of Comparative Example 1 at a dose of 4 mg / animal (IN 4 mg) and adrenaline in aqueous solution (1 mg / mL) at a dose of 0.3 mg / animal (IM 0.3 mg). The composition of Comparative Example 1 was administered intranasally by a specific intranasal device from Aptar Pharma, France (UDS Monopowder).
[0234] Aqueous solutions of adrenaline were administered intramuscularly into the left hind leg musculature (quadriceps muscle), with a washout period of 48 hours between each administration.
[0235] The in vivo part of the study was carried out in accordance with the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (ETS No. 123).
[0236] Blood samples were collected under conventional sterile conditions from all dogs at the designated time points via the cephalic or saphenous vein. A volume of 1 mL was collected in a plastic Vacuette® tube containing K3EDTA. Blood samples were kept on ice before being centrifuged at 3500 rpm for 10 minutes at +4°C.
[0237] Plasma was extracted and transferred to pre-labeled cryovials containing sodium metabisulfite as an antioxidant and stored at -80°C until transport for bioanalysis. Scheduled sampling time points were as follows: -5 (pre-dose), 2.5, 5, 10, 15, 20, 30, 45, 60, and 90 min post-dose.
[0238] Frozen plasma samples were shipped to Recipharm OT, Uppsala, Sweden for bioanalysis. Plasma concentrations of adrenaline were determined using HPLC-MS-MS analysis, which allows measuring the concentration of adrenaline in dog plasma in the range of 0.05-100 ng / mL, using adrenaline-D6 as a deuterated internal standard. Analytes were extracted from sample plasma using protein precipitation with TCA. After centrifugation, the supernatant was used for analysis.
[0239] All samples were analyzed by first separating the analytes using an Acquity HSS T3 column (2.1mm*100mm, 1.7μm) and then detecting them using positive electrospray ionization and multiple reaction monitoring (MRM). Quantification was performed in the range of 0.05-100ng / mL.
[0240] Pharmacokinetic parameters were calculated by non-compartmental analysis using Phoenix WinNonlin (v8.0) and are shown in Table 3 below. AUC last is the area under the plasma concentration versus time curve up to the last sampling point, and C max is the maximum measurable concentration after administration, and t max is the time to maximum measurable concentration. Values shown in Table 3 are the average of N=6. [Table 3]
[0241] Comparative Example 4 Epinephrine (adrenaline) preparations produced by spray drying in air. Eight aqueous solutions (50 g each, formulations A to I respectively) containing dry matter compositions each having 0.364 g adrenaline bitartrate and having the respective amounts of excipients lactose monohydrate, maltodextrin (Glucidex IT 12 DE), HPMC (Methocel K3), sucrose monolaurate (D-1216), sodium metabisulfite (Merck Chemical & Lifescience AB, Sweden), and / or disodium EDTA (Titriplex® III, Merck Chemical & Lifescience AB, Sweden) shown in Table 4 below in grams were spray dried according to the general procedure described in Comparative Example 1 above to produce a fine, dry, free-flowing powder with a nominal dose of 1.0 mg adrenaline free base in 25 mg powder. [Table 4]
[0242] The PSD of the resulting powder was determined as described in Comparative Example 1 and is shown in Table 5 below, and was well within a distribution suitable for nasal administration. [Table 5]
[0243] The initial assay and purity (expressed as RS%) as determined by HPLC / UV analysis are shown in Table 6 below. [Table 6]
[0244] Chemical stability experiments were performed essentially as described in Comparative Example 2 above by packaging vials containing various adrenaline formulations in heat-sealed aluminum pouches with 4 Å molecular sieve desiccant and storing them in a 40 / 75 climate cabinet.
[0245] The chemical stability after up to 12 months is summarized for the various compositions in Table 7 below, along with the total amount of impurities and decomposition products expressed as RS%. [Table 7]
[0246] The observed change in RS% for the readily degraded adrenaline indicates surprisingly good chemical stability of the drug substance when formulated as described above.
[0247] Comparative Example 5 Epinephrine (adrenaline) formulations produced by spray drying under nitrogen. Five aqueous solutions (50 g each, Formulations J-N respectively) containing dry matter compositions each having 0.218 g adrenaline bitartrate and having the respective amounts of excipients lactose monohydrate, maltodextrin (Glucidex IT 12 DE), HPMC (Methocel K3), sucrose monolaurate (D-1216), and / or sodium metabisulfite as shown in Table 8 below in grams were spray dried by the general procedure described in Comparative Example 1 above, except that nitrogen was used instead of air as the drying gas, to produce a fine, dry, free-flowing powder having a nominal dose of 1.0 mg adrenaline free base in 25 mg powder. [Table 8]
[0248] The initial assay and purity (expressed as RS%) as determined by HPLC / UV analysis are shown in Table 9 below. [Table 9]
[0249] Chemical stability experiments were performed essentially as described in Comparative Example 2 above by packaging vials containing various adrenaline formulations in heat-sealed aluminum pouches with 4 Å molecular sieve desiccant and storing them in a 40 / 75 climate cabinet.
[0250] The chemical stability after up to 12 months is summarized for the various compositions in Table 10 below, along with the total amount of impurities and decomposition products expressed as RS%. [Table 10]
[0251] Example 1 Evaluation of various disaccharides and maltodextrins. Nine aqueous solutions (50 g each, formulations O to W respectively) containing dry matter compositions each having 0.364 g adrenaline bitartrate (Transo Pharm, Taiwan) and having the respective amounts of disaccharides (lactose monohydrate (LT), trehalose (TH, Sigma-Aldrich (Merck), Sweden), sucrose (SU), and maltose (MT) (both Merck, Germany), maltodextrins (Glucidex IT 6DE, Glucidex IT 12 DE or Glucidex IT 19 DE, all Roquette, France), and sucrose monolaurate (D-1216, SM) shown in Table 11 below in grams were spray dried according to the general procedure described in Comparative Example 1 above to produce a fine, dry, free-flowing powder with a nominal dose of 1.0 mg adrenaline free base in 25 mg powder. [Table 11]
[0252] Chemical stability experiments were performed essentially as described in Comparative Example 2 above by packaging vials containing various adrenaline formulations in heat-sealed aluminum pouches with 4 Å molecular sieve desiccant and storing them in a climatic cabinet at 40 / 75 and in a conventional oven at 50° C. and ambient RH.
[0253] The chemical stability after up to 1 month (40 / 70) and up to 4 weeks (50° C.) is summarized for the various compositions in Table 12 below, along with the total amount of impurities and decomposition products expressed as RS%. [Table 12]
[0254] Example 2 Storage stability Commercially available EpiPens (Meda Pharma GmbH & Co. KG, Germany), which had a shelf life of approximately 9–12 months remaining upon arrival at the analytical laboratory, were purchased from a pharmacy.
[0255] Chemical stability experiments were performed essentially as described in Comparative Example 2, storing the EpiPens in a climate cabinet at 40 / 75. Chemical stability after up to 3 months is summarized for various compositions in Table 13 below, along with the total amount of impurities and decomposition products expressed as RS%. [Table 13]
[0256] In a separate experiment, three Epipen auto-injectors, one in its original packaging (control), one with the outer box removed (original), and one stripped from its plastic protective packaging leaving only the glass syringe containing the product (syringe only), were placed in a light box and exposed to 1.2 million lux of UV light for 18 hours. Formulation S (see Example 1 above), and Formulation W 1(having the same composition as Formulation W in Example 1 above, but prepared on a larger scale) was also subjected to the same direct light exposure. Chemical stability is summarized for the various compositions in Table 14 below, along with the total amount of impurities and decomposition products expressed as RS %. [Table 14]
[0257] The anti-meric purity of the samples (Epipen, formulation A from Comparative Example 4 above, and formulation W 1 (see above)) was also determined by chiral HPLC after storage for up to 6 months at 40 / 75 according to standard USP-based methods.
[0258] The antimerical stability, expressed as (% of S-adrenergic), is summarized for the various compositions in Table 15 below. [Table 15]
[0259] Example 3 Evaluation of different doses of adrenaline using trehalose and different maltodextrins. Four aqueous solutions (50 g each, Formulations X through AA, respectively), each containing a dry matter composition having the respective amounts of adrenaline bitartrate (Transo Pharm, Taiwan), trehalose, maltodextrin (Glucidex IT 12 DE or Glucidex IT 19 DE), and sucrose monolaurate (D-1216) shown in Table 16 below in grams, were spray dried by the general procedure described in Comparative Example 1 above to produce a fine, dry, free-flowing powder having a nominal dose of 1.0 mg or 3.0 mg of adrenaline free base in 25 mg of powder. [Table 16]
[0260] Chemical stability experiments were performed essentially as described in Comparative Example 2 above by packaging vials containing various adrenaline formulations in heat-sealed aluminum pouches with 4 Å molecular sieve desiccant and storing them in a 40 / 75 climate cabinet.
[0261] The chemical stability after up to one month is summarized for the various compositions in Table 17 below, along with the total amount of impurities and decomposition products expressed as RS%. [Table 17]
[0262] All formulations disclosed in Comparative Examples 4 and 5 above, as well as formulations containing maltodextrins having a DE of less than 15 (e.g., 6 or 12) in Examples 1 and 3 above, were found to be slightly cloudy when observed visually unless 40% disaccharides were used, which clarified the solution.
[0263] All formulations disclosed in Examples 1 and 3 above in which the maltodextrin has a DE greater than 15 (eg, 19) were found to be non-turbid upon visual observation.
[0264] Example 4 The lowest measurable Tg value Approximately 6-9 mg samples of the various formulations identified in Table 18 below were weighed into individual Differential Scanning Calorimetry (DSC) crucibles and equilibrated in open vials at 0%, 11%, 22%, 33%, and 43% RH conditions as follows:
[0265] For the 0% RH condition, a silica gel / molecular sieve desiccant was used, and for the other four RH conditions, saturated salt solutions were used as humidifiers as follows: 11% RH-LiCl, 22% RH-CH3COOK, 33% RH-MgCl2, and 43% RH-K2CO3.
[0266] Each sample was then capped and analyzed using modulated DSC to determine the apparent glass transition temperature (Tg).
[0267] DSC was performed using a Netzsch DSC 204F1 instrument. The glass transition temperature (Tg value) for each of the investigated formulations was determined using a sealed ampoule or a perforated lid (0% RH). A hermetic lid was fitted and crimped onto the hermetic pan of all samples stored with a saturated salt solution.
[0268] For 0% RH conditions, a conventional DSC pan with a lid that had a 0.3 mm hole drilled in the lid by the instrument was used. This was done to promote completely dry conditions during the experiment, when the sample was surrounded by nitrogen in the instrument and any moisture potentially absorbed during the heating phase would be released.
[0269] For the remaining samples, the DSC lid was airtight throughout the entire DSC run. Because the gas space around the sample in the cup was very small, strictly limiting the amount of water present in the gas phase at equilibrium, and because the experimental time was very short, it can be inferred that equilibrium water was maintained in the sample throughout the experiment, despite the increased temperature for all Tg values in the lower temperature range.
[0270] Each sample was analyzed using a modulated temperature profile with an average heating rate of 5 K / min, a modulation period of 20 seconds, and an amplitude of ±0.5 K. The starting minimum temperature was 0° C. and the maximum temperature was 200° C. Before heating, the temperature was held at 0° C. for 15 minutes.
[0271] Formulations prepared according to Examples 1 and 2 above were analyzed and the Tg measurements are shown in Table 18 below. [Table 18]
[0272] In comparison, Formulation D, prepared according to Comparative Example 4 above, exhibited a Tg of 78° C. at 0% RH, 64° C. at 11% TH, and 59° C. at 33% RH.
[0273] All of the above values are considered acceptable.
[0274] Example 5 Intranasally administered epinephrine - a pharmacokinetic study (healthy volunteers) Four 1 mg epinephrine nasal powder formulations (Formulations 1-4) were made essentially as described in Comparative Example 1 above (except the spray dryer feed rate was set at 4.0 g / min) and with varying amounts of trehalose and maltodextrin as shown in Table 19 below. [Table 19]
[0275] A Phase I clinical study was conducted with the primary objective of determining the bioavailability of four epinephrine nasal powders versus the reference commercial product, EpiPen® ("Reference", Epinephrine, Intramuscular Injection, 0.3 mg, Meda AB, Solna, Sweden).
[0276] Secondary objectives were to characterize additional PK parameters, compare pharmacodynamic (PD) effects on systolic / diastolic blood pressure (SBP / DBP), mean arterial blood pressure (MAP), and heart rate (HR) between treatments, and evaluate the safety and tolerability of the investigational formulation.
[0277] This study was a randomized sequence, single-center, open-label, five-period crossover study to evaluate the comparative bioavailability of four powder formulations for intramuscular epinephrine injection in healthy subjects.Each subject received each of formulations 1-4, as well as Ref, consecutively according to a pre-established randomization schedule, separated by a 24-h washout period.
[0278] Subjects were randomized immediately prior to administration of the first dose of the relevant investigational medicinal product (IMP) or reference (if used). A computer-generated randomization schedule was used to assign subject numbers to one of 10 treatment sequences.
[0279] Approximately 65 subjects were screened for inclusion in the study within 28 days prior to dosing. Forty eligible subjects (healthy men or women, non-pregnant, non-lactating, aged 18-55 years, with a body mass index of 18.5-30.0 kg / m2) were recruited. 2 subjects) were admitted to the clinical unit the night before IMP administration (day −1) and remained on-site until discharge 24 h after their final dose (after receiving all five treatments).
[0280] Formulations 1-4 were administered intranasally by a specific intranasal device from Aptar Pharma, France (UDS Monopowder). Subjects received an IMP or a referral on the mornings of days 1, 2, 3, 4, and 5 with appropriate intersubject intervals (approximately 10 min) based on logistical requirements. On each dosing day, an IMP was administered in alternate nostrils. A follow-up phone call was conducted 3-5 days after the final dose to ensure the subjects' continuing well-being.
[0281] Of the 40 subjects enrolled, 37-39 underwent all IMPs and referrals. For analysis purposes, 37-39 subjects were included in the safety population, safety analysis dataset, and PK population.
[0282] Plasma concentrations of epinephrine were analyzed using non-compartmental methods to obtain estimates of standard PK parameters, as follows: [Table 20]
[0283] The following parameters were used to analyze the PD effect: [Table 21]
[0284] Evaluation of safety parameters consisted of analysis of adverse events (AEs), local tolerability, laboratory evaluations, vital signs, electrocardiograms (ECGs), and physical examination findings.
[0285] Log-transformed exposure parameters (AUC and Cmax) were compared with standard methods to assess relative bioavailability. A single mixed-effects model was fitted to each parameter to obtain estimates of geometric mean ratios (GMRs) and corresponding confidence intervals (CIs) for all treatment comparisons of interest. The model included terms for treatment actually received, study day (i.e., period), and design sequence fitted as fixed effects and subjects within sequence fitted as random effects. Results were back-transformed to a linear scale and presented. The following comparisons were of interest: Relative bioavailability compared to the reference: IMP of AUC(0~t), AUC(0~inf), and Cmax: reference GMR was determined Partial AUCs compared to the reference:IMP:reference GMRs for AUC(0–10), AUC(0–20), AUC(0–30), AUC(0–45), and AUC(0–60 min) were determined.
[0286] For PD parameters, comparisons were made using arithmetic mean differences and corresponding 90% confidence intervals.
[0287] result The arithmetic mean epinephrine plasma concentrations versus time (linear scale) by treatment are shown in Figure 8. The geometric mean epinephrine plasma concentrations versus time (semi-log scale) by treatment are listed in Table 20 below. [Table 22]
[0288] The analysis of relative bioavailability (GMR, CI 90%) is shown in Table 21 below. [Table 23]
[0289] All IMP formulations demonstrated higher overall plasma exposure and similar or higher peak plasma exposure of epinephrine compared to the reference.
[0290] Table 22 below shows descriptive statistics for epinephrine partial AUC (as geometric mean, geometric CV%) by treatment. Table 23 shows the partial AUC for Formulations 1-4 compared to the reference (GMR, 90% CI). [Table 24] [Table 25]
[0291] All IMP formulations demonstrated plasma epinephrine exposures equal to or higher than the reference in the first 20 minutes after dosing.
[0292] The effects of all IMP formulations and the reference on systolic (Table 24) and diastolic (Table 25) blood pressure are shown below. [Table 26] [Table 27]
[0293] The effects of all IMP formulations and the reference on mean arterial blood pressure are shown below in Table 26 and the effects on heart rate are shown in Table 27, respectively. [Table 28] [Table 29]
[0294] Tables 28-31 show the PD parameters of formulations 1-4 compared to the reference (arithmetic mean difference, 90% CI). Table 28 shows the comparison of systolic blood pressure (SBP), Table 29 for diastolic blood pressure (DBP), Table 30 for mean arterial blood pressure (MAP) and Table 31 for heart rate (HR). [Table 30] [Table 31] [Table 32] [Table 33]
[0295] For SPB, DBP, and MAP (Tables 28-30), AUEC parameters and Emax were significantly higher (90%CI>0) for all IMPs compared to the reference. For HR (Table 31), most IMPs had higher AUEC parameters and tended to have higher Emax compared to the reference.
[0296] All epinephrine nasal powder formulations (1-4) had higher total epinephrine exposure (AUC(t)) than the reference and similar or higher Cmax compared to the reference. Tmax was slightly lower than the reference for formulations 1-4, but after 20 minutes, all four epinephrine nasal powder formulations had similar or higher epinephrine exposure than the reference, as shown in Table 23.
[0297] Intranasal epinephrine nasal powder was deemed safe, and no serious adverse events (AEs) were reported in this study. The most commonly reported AEs were nasal discomfort, nasal pain, headache, and palpitations.
Claims
1. 1. A pharma- ceutically acceptable composition in the form of a solid, amorphous, monoparticulate powder, comprising: (a) a pharmacologically effective dosage of an adrenoceptor modulator or a pharma- ceutically acceptable salt thereof; (b) a pharma- ceutically acceptable composition comprising a mixture of a pharma- ceutically acceptable carrier material, the carrier material comprising a maltodextrin having a dextrose equivalent (DE) of greater than 15.
2. 10. The composition of claim 1, wherein the carrier material further comprises a disaccharide selected from the group consisting of maltitol, trehalose, sucralose, sucrose, isomalt, maltose, and lactose.
3. The composition of claim 2 , wherein the disaccharide comprises lactose and / or trehalose.
4. 4. The composition of claim 2 or 3, wherein the carrier material comprises a combination of trehalose and maltodextrin 19DE.
5. 5. The composition of claim 2, wherein the weight ratio of disaccharide:maltodextrin based on the total weight of the composition is in the range of about 10:1 to about 1:
8.
6. 10. The composition of any one of the preceding claims, wherein the lowest measurable glass transition temperature of the composition is at least about 35°C when measured at a relative humidity of up to about 35%.
7. 2. The composition of any one of the preceding claims, wherein the composition further comprises a sucrose ester.
8. The composition of claim 7 , wherein the sucrose ester comprises sucrose monolaurate.
9. 10. A composition according to any one of the preceding claims, suitable and / or adapted for nasal delivery.
10. 10. The composition of claim 9, wherein the particle size distribution comprises a D10 greater than about 3 μm.
11. The composition of claim 9 or 10, wherein the powder has a particle size distribution with a volume-based mean diameter in the range of about 10 μm to about 100 μm.
12. 10. The composition of any one of the preceding claims, wherein the pharmacologically effective dosage of an adrenoceptor agonist or salt thereof is from about 1 μg to about 100 mg.
13. 2. A composition according to any one of the preceding claims, wherein the adrenoceptor modulator is epinephrine (adrenaline).
14. 14. The composition of claim 13, wherein the pharmacologically effective dosage of epinephrine is from about 0.1 mg to about 10 mg.
15. The composition of claim 14, wherein the dosage is from about 0.5 mg to about 3 mg.
16. A process for the manufacture of a composition according to any one of the preceding claims, said process comprising: i) mixing said adrenoceptor modulator or a pharma- ceutically acceptable salt thereof with said pharma- ceutically acceptable carrier material together in a suitable volatile solvent; ii) spray drying the mixture from step i).
17. A composition obtainable by the process of claim 16.
18. A nasal applicator device suitable and / or adapted for delivering a composition according to any one of claims 1 to 15 or 17 to the nose, the nasal applicator device comprising or associated with and / or attached to a reservoir within which the composition is contained.
19. 20. A process for manufacturing an applicator device as described in claim 18, comprising the process described in claim 16, followed by loading the composition so formed into a reservoir within or associated with or attached to the applicator device.
20. A composition according to any one of claims 13 to 15 or 17 for use in the treatment of an allergic disorder.
21. Use of a composition according to any one of claims 13 to 15 or 17 for the manufacture of a medicament for the treatment of allergic disorders.
22. 18. A method of treatment of an allergic disorder, the method comprising administration of a composition according to any one of claims 13 to 15 or 17 to a patient suffering from or prone to said condition.
23. 23. The composition for use according to claim 20, the use according to claim 21, or the method according to claim 22, wherein the allergic disorder comprises an allergic reaction to an insect sting or bite, a food or a drug, and / or another chemical.
24. 24. The composition, use or method for use of claim 23, wherein the reaction comprises anaphylaxis.
25. 25. A composition, use or method for use according to claim 23 or 24, wherein the composition is administered to the nose by an applicator according to claim 18.
